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EPIDEMIOLOGY OF BREAST CANCER
Breast cancer is the leading cause of cancer-related death in women. In 2016, almost 
1.7 million women globally were diagnosed with breast cancer. In the same year, 
more than half a million women died due to this disease (1). Survival rates of breast 
cancer patients have improved over the last decade, mainly due to improvements 
in organized screening, early diagnosis and treatment modalities (2).
PROGNOSTIC MARKERS IN STANDARD CLINICAL 
CARE AND NEW PROGNOSTICATORS
Breast cancer is a heterogeneous disease with different morphological and 
biological features. This leads to differences in clinical behavior and response to 
treatment. Tailor-made treatment is a promising strategy to improve prognosis. 
Prognostic markers are important to identify patients with a high or low risk of 
disease relapse and cancer-related death. By identifying patients with a low risk 
of recurrences, patients can be spared from adjuvant treatment. This will result 
in decreased overtreatment and harmful side effects, such as heart failure and 
cognitive dysfunction (3). On the other hand, selecting patients with an aggressive 
type of breast cancer will decrease the risk of undertreatment and thereby the risk 
of recurrence or breast cancer-related death.
An online tool frequently used in daily practice for the estimation of prognosis 
and expected adjuvant treatment benefit in patients diagnosed with early invasive 
breast cancer primarily treated with surgery is the PREDICT (4). The prognostic 
parameters used in this tool are based on features of the tumor cells and patient 
characteristics. The PREDICT includes age, post-menopausal status, estrogen 
receptor (ER) status, human epidermal growth factor receptor 2 (HER2) status, 
Ki67 status, tumor size, lymph node involvement, differentiation grade and mode 
of detection. This prediction tool helps clinicians and patients in decision-making 
about adjuvant therapies by calculating the expected 5-, 10- and 15-year overall 
survival. Moreover, the online program provides the beneficial value of post-
operative treatment options (chemotherapy, endocrine therapy, trastuzumab and 
bisphosphonates) (5, 6). During the last decades, a great amount of research has 
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been performed to develop new prognostic biomarkers and tests. Gene expression 
profiling tests, such as the MammaPrint (70-gene profile) and Oncotype DX Breast 
Cancer Assay (20-gene profile) are well investigated (7, 8). The Dutch national 
guidelines recommend these tests in case of doubt about the indication of adjuvant 
chemotherapy for patients older than 35 years diagnosed with invasive carcinoma 
of no special type (NST).
In 2011, Hanahan et al. published an important update in Cell on the role of the 
tumor microenvironment in cancer development. The authors determined that 
the tumor microenvironment plays a pivotal role in tumorigenesis (9). Although 
increasing efforts have focused on the research of the tumor microenvironment, 
no markers of the microenvironment have been implemented in standard clinical 
care in the Netherlands yet. Cancer cells and the tumor microenvironment are 
in a complex interplay and evolve continuously during tumor progression (10). 
Cancer cells recruit and activate non-neoplastic cells, such as fibroblasts, the 
extracellular matrix, cells evolved in a vascular network and immune cells (11). 
The non-neoplastic cells secrete proteins which contribute in tumor progression, 
such as vascular endothelial growth factor, stromal cell-derived factor 1, platelet-
derived growth factor and transforming growth factor-β. Also, cancer-associated 
fibroblasts are thought to be strongly involved in cancer progression (12). Immune 
cells are an important component of the tumor microenvironment and have either 
an antitumorigenic or protumorigenic effect on cancer development. A prognostic 
marker involving the tumor microenvironment are tumor-infiltrating lymphocytes 
(TILs). TILs show to have prognostic and predictive value in breast cancer patients 
(13-17), but are not integrated into standard clinical care yet.
Another tumor microenvironment derived prognostic marker, which is the main 
topic of this thesis, is the tumor-stroma ratio (TSR). Assessment of this parameter 
is quick, easy to perform and inexpensive. The scoring is performed on routine 
hematoxylin and eosin (H&E) stained tissue slides with a conventional light 
microscope (18). The TSR represents the proportion of stroma versus tumor cells 
in the most stroma-abundant field of a primary tumor. Mesker et al. first described 
this scoring method in 2007 (18). Since then, this method is validated in various 




cancer patients with a stroma-high tumor have a worse clinical outcome compared 
to patients with a stroma-low tumor. Chapter 2 discusses the studies published on 
the prognostic value of the TSR in breast cancer patients with special attention to 
the effect on clinical outcome in patients with triple-negative tumors. This review 
also provides an insight into the methods used for the TSR assessment and the 
rationale behind the importance of tumor-associated stroma.
Further research presented in this thesis aims (1) to optimize the prognostic 
impact of the TSR in subgroups of breast cancer patients and (2) to investigate the 
prognostic impact of the TSR in combination with other tumor-related parameters.
Clinically relevant subgroup analyses in a heterogeneous disease
Breast cancer is a heterogeneous disease and can be divided into different 
subgroups. Firstly, a subdivision can be made based on the histological type, of 
which invasive carcinoma of NST is the most common subgroup. The diversity 
in histological aspects is already translated into this specific subgroup, as the 
World Health Organization (WHO) describes invasive carcinoma of NST as a 
group of tumors which do not possess specific characteristics to be classified in a 
particular histological type. This is in contrast to lobular carcinomas, which are 
the second most common histological group (43). The various histological subtypes 
are associated with different outcomes. For example, papillary tumors have better 
outcomes compared to invasive lobular carcinomas (44).
Subgroups can also be based on ER, progesterone receptor (PR) and HER2 status. 
These parameters have a prognostic and predictive value and are therefore assessed 
in routine clinical care (44). Furthermore, breast cancer can also be divided into 
four molecular subtypes based on gene expression; luminal A, luminal B, HER2-
enriched and basal-like tumors.
Tumor grade is part of the standard evaluation of breast cancer tissue and is a robust 
prognostic parameter used in clinical decision-making and online tools such as the 
PREDICT. The tumor grade is classified into three groups (low, intermediate and 
high) based on the pathological evaluation of tubule and gland formation on H&E 
slides, nuclear polymorphism and mitotic counts (45).
Chapter 3 elaborates on the prognostic impact of the TSR in clinically relevant 
subgroups of breast cancer patients. In this chapter, the effect of TSR assessment, 
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categorized in stroma-low and stroma-high, on breast cancer-specific survival and 
recurrence-free survival is evaluated in the largest cohort published so far.
Older women with breast cancer
A major risk factor for breast cancer development in women is aging (46). At the 
moment, the majority of women are older than 65 years at the time of diagnosis, 
and the incidence will increase as the general population is aging (46-48). The 
significant improvement in survival rates in younger women with breast cancer 
in the last 30 years has not been observed in older patients (49). Disease-specific 
mortality is often underestimated in older patients (50). This may suggest that older 
patients may be undertreated, as at the moment, few patients over the age of 70 
receive chemotherapy. More accurate identification of disease aggressiveness in 
the older patient is necessary to improve the selection of patients who will benefit 
from extensive adjuvant therapy in order to reduce the gap in survival rates between 
younger and older patients with breast cancer.
Tumor biology in older patients is different compared to their younger counterparts. 
The tumors of older patients have shown to possess lower proliferation rates, to be 
genetically more stable and more often ER-positive (51). Furthermore, differences 
between younger and older patients with breast cancer are observed in the 
extracellular matrix and products secreted by senescent fibroblasts (52). Research 
showed that the molecular profile of the tumor microenvironment is age-dependent. 
For instance, induced stromal features associated with a senescence-associated 
secretory profile and autophagy which promote tumorigenesis are observed in older 
patients with triple-negative tumors (53).
In chapter 4, the differences in the amount of intra-tumoral stroma with the increase 
of age are evaluated by the assessment of the TSR. Moreover, the prognostic value 
of the TSR in older patients with breast cancer is assessed.
Tumor-positive axillary lymph nodes
The presence of lymph node metastasis are an important prognostic factor for 
predicting long-term clinical outcome (54). Axillary lymph node dissection 
(ALND) was standard therapy in patients with tumor-positive lymph nodes before 
the introduction of the sentinel node biopsy (SNB). Recent studies show that not all 




Downsizing therapy to prevent overtreatment is desirable, for example, to minimize 
unnecessary side effects, such as invalidating lymphoedema of the arm after ALND.
Chapter 5 evaluates the prognostic impact when adding TSR assessment of the 
tumor-positive lymph nodes to TSR assessment of the primary tumor alone. This 
might lead to a better stratification of high-risk patients and finally to improved 
decision-making concerning treatment.
Immune infiltration in breast cancer
On the one hand, immune cells are an important component of the tumor 
microenvironment. The immune system can control tumor progression, but on 
the other hand, the tumor cells can acquire modalities to escape the host immune 
system through their genetically unstable appearance (55, 56). Immune infiltration 
in breast cancer is related to prognosis and treatment response. For example, the 
presence of regulatory T cells (Tregs) is associated with a poor prognosis (57).
In chapter 6, the prognostic value of the immune status of tumors combined with 
the TSR is evaluated. The immunological markers included in the immune status 
are markers which play a role in tumor control and escape; cytotoxic T lymphocytes 
(CTLs), Tregs, classical human leukocyte antigen (HLA) class I (HLA-A, HLA-B 
and HLA-C), non-classical HLA class I (HLA-E and HLA-G) and natural killer 
(NK) cells.
These immunological markers are selected based on biological rationale and 
interactions; classical HLA class I presents tumor-associated antigens on the cell 
surface of the tumor and CTLs recognize the presented tumor-associated antigens 
(58). Tumor cells can downregulate HLA expression to escape recognition by CTLs, 
but make them more prone to NK cell recognition (59). Expression of non-classical 
HLA class I can inhibit the function of NK cells (59-61). Furthermore, tumor cells 
can attract and activate Tregs and thereby contribute to tumor progression (62).
Finally, chapter 7 summarizes and discusses the published research in this 
thesis and describes future perspectives. The summary in Dutch is presented 
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The prognostic value of the tumor-
stroma ratio in primary breast cancer 
with special attention to triple negative 
tumors: a review





There is a strong need to improve the prognostication of breast cancer patients in 
order to prevent over- and undertreatment, especially when considering adjuvant 
chemotherapy. Tumor stroma characteristics might be valuable in predicting disease 
progression.
Methods
Studies regarding the prognostic value of the tumor-stroma ratio (TSR) in breast 
cancer were evaluated.
Results
A high stromal content was related to a relatively poor prognosis. The most 
pronounced prognostic effect of this parameter seemed to be observed in the triple-
negative breast cancer subtype.
Conclusions
TSR assessment might represent a simple, fast and reproducible prognostic factor 
at no extra costs, and could be incorporated into routine pathological diagnostics. 
Despite these advantages, robust clinical validation of this parameter has yet to be 





According to the European cancer statistics for 2018, the estimated number of new 
breast cancer cases is 522.500 and the estimated number of breast cancer related-
deaths is 137.700 (1). Breast tumors are classified into four molecular subtypes, 
namely luminal A, luminal B, human epidermal growth factor receptor 2 (HER2)-
enriched and basal-like (2, 3). The triple-negative breast cancer (TNBC) belongs to 
the basal-like phenotype in the vast majority, which is an aggressive form of breast 
cancer with a shorter relapse-free period (RFP) and relative survival compared to 
luminal A and B (4, 5). However, gene-expression analyses have shown that this 
group is notoriously heterogeneous, with some molecular subtypes even associated 
with a relatively favorable prognosis (5). Approximately 16% of all breast cancer 
cases are represented by TNBC (6).
In recent years, extensive research has been performed to discover new prognostic 
biomarkers and determine optimal prognostication schemes for breast cancer 
patients. Molecular tests, such as the 70-gene signature (MammaPrint, Agendia 
BV, The Netherlands) and the 21-gene assay (Oncotype DX, Genomic Health, 
United States) have shown to improve clinical decision making in early-stage 
breast cancer of certain molecular and clinical subtypes, such as estrogen receptor 
(ER)-positive or HER2-negative breast cancer (7, 8). These molecular markers are 
now endorsed into routine clinical practice, according to the American Society 
of Clinical Oncology Clinical Practice guideline, to reduce the administration of 
adjuvant chemotherapy and prevent overtreatment (9).
Despite the fact that alterations in the tumor microenvironment have been 
recognized as important drivers of tumor progression, the tumor environment has 
not been integrated in routine clinical decision making yet. A parameter which 
translates the amount of tumor-associated stroma is the tumor-stroma ratio (TSR), 
which has been extensively described as a rich source of prognostic information 
for various solid cancer types (10-38). The TSR was first described as a prognostic 
factor in breast cancer in 2011 by De Kruijf et al. and has been validated in 
numerous studies (12-15, 17).
For TSR assessment, the amount of tumor-associated stroma is determined on 
routine hematoxylin and eosin (H&E) stained slides of the primary tumor tissue. 
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Each tumor is assigned to either the stroma-high or stroma-low category based on 
a set cut-off value (10).
In this review, literature investigating the effect of the TSR as a prognostic factor 
in female breast cancer is discussed with a special interest in the prognostic effect 
in TNBC patients.
RATIONALE
The influence of the tumor-associated stroma on epithelial tumor progression is 
mostly derived from functional in vitro studies. Similarly, those in vitro studies have 
demonstrated events in the stromal compartment that occur during carcinogenesis 
and could contribute to tumor progression. The production of growth factors and 
proteases by cancer cells initiate changes in the stromal environment (39). Those 
alterations lie within remodeling of the matrix, recruitment of fibroblasts, the 
migration of immune cells and angiogenesis, all contributing to tumor progression 
(40). Cancer-associated fibroblasts (CAFs) contribute to carcinogenesis through 
the development of unique functions, including an amplified extracellular matrix 
(ECM) production, higher proliferation rate and the secretion of several cytokines, 
like vascular endothelial growth factor (VEGF), stromal cell-derived factor 
1 (SDF1) and platelet-derived growth factor (PDGF), leading to angiogenesis 
(40). Transforming growth factor-β (TGF-β) is another factor that is thought to 
be strongly involved in the tumor-promoting effects of CAFs as described in 
colon cancer by Hawinkels et al. (41). Those behavioral modifications lead to an 
elevated expression of enzymes, like matrix metalloproteinases (MMPs), resulting 
in remodeling and deposition of the ECM, with concurrently the release of pro-
angiogenic factors (42).
The ECM is frequently disorganized in tumors. One of the most important 
mechanisms in the ECM contributing to tumor progression is collagen crosslinking. 
Due to crosslinking collagen by lysyl oxidase (LOX), the ECM of the tumor 
becomes more stiff, leading to increased focal adhesions and enhanced PI3K 
signaling, thereby indirectly ensuring tumor progression (43). Besides the fact 
that alterations in the tumor niche lead to progression directly, the tumorigenesis 




pro-angiogenic factors by CAFs and immune cells. Thus, during the process of 
tumorigenesis, changes occur in the organization of stromal cells, contributing 
both directly and indirectly to tumor growth and progression.
Previous studies investigating gene-expression profiles in stromal cells have 
demonstrated gene signatures related to clinical outcome and response to treatment 
in breast cancer (44, 45). Clinical application of these signatures was impractical 
and a definitive indication was never discovered. However, these studies did provide 
a strong indication that valuable clinical information was ignored by solely focusing 
on the epithelial compartment. As the stromal processes that are reflected by these 
assays likely have a quantitative relationship with the amounts of stromal tissue 
within the tumor, quantitative stromal parameters might equally express prognostic 
information just by morphology alone (45).
METHODS USED FOR TSR ASSESSMENT
In literature, two methods are described for TSR assessment in breast cancer. The 
visual scoring method utilized by Mesker et al. and the automated point counting 
method, a semi-automated approach, utilized by West et al. (10, 18).
Visual eyeballing
Mesker et al. and others determined the TSR by visual eyeballing (10, 12-17). 
The microscopic determination of the amount of stroma in the primary tumor 
is performed on routine H&E stained slides. A 2.5x or 5x objective is used to 
determine the most stroma-abundant area on the slide. In this area, image-fields 
with tumor cells at all borders of the image are used to determine the amount of 
stroma, using a 10x objective. The stroma percentage is estimated in increments of 
10% per image-field, considering the highest scored stroma percentage as decisive. 
A stroma percentage ≤50% is categorized as stroma-low and a stroma percentage 
>50% is categorized as stroma-high, based on the statistical determination, initially 
performed on colon cancer and subsequently verified for breast cancer (figure 1) 
(10, 18). Considerable segments of necrosis or in situ tumors were excluded in the 
evaluation of the TSR by neglecting them in the analysis (12, 14).
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FIGURE 1. Microscopic evaluation of the tumor-stroma ratio on hematoxylin and 
eosin stained sections of breast tumors with a 10x objective categorized in stroma-high 
tumors (>50% stroma) and stroma-low tumors (≤50% stroma) by visual eyeballing. 
a. Stroma-high b. Stroma-low.
a. b.
Semi-automated point counting
West and colleagues have objectified the measurement by evaluating the tumor 
tissue slides in colon carcinoma using 300 random measurement points validated 
for breast cancer by Downey et al. (18, 46, 47). Four-micrometer-thick H&E stained 
sections are scanned using a 20x objective and subsequently two areas without large 
segments of necrosis are selected with a digital slide viewer. In this method, the two 
sampled 9 mm2 areas are in the tumor-leading edge, as well as in the non-leading 
edge. The group utilizes a grid with a sample of 300 random points, superimposed 
on the selected area. Under each of the 300 points, the histopathology is categorized 
in ‘tumor’, ‘stroma’ or ‘unclassified’ (necrosis, blood vessels, inflammation, etc.). 
The ultimate TSR is the proportion of ‘stroma’ under the 300 points, compared with 
all points per section. In other words, the TSR is the number of points, categorized 
as ‘stroma’ divided by the total number of points, categorized as ‘tumor’ and 
‘unclassified’ (18, 46, 47). Downey et al. used 0.49 (i.e. 49%) as a cut-off value in 




statistical analysis (46). However, in another study, cut-off values of 0.31 for OS 
and 0.46 for DFS are used for categorizing the TSR (47).
The inter-observer variation of these two methods, determined by the Cohen’s 
kappa coefficient (K) or intraclass correlation coefficient (ICC), lies in the range 
of 0.68-0.85, indicating substantial to good agreement between observers in both 
methods (table 1).
THE TUMOR-STROMA RATIO IN BREAST CANCER 
PATIENTS
The first study on the TSR in breast cancer was published by De Kruijf et al. (12). 
The TSR was estimated by visual eyeballing according to the method described by 
Mesker et al. (10). The authors showed that the TSR was an independent prognostic 
parameter in 574 breast cancer patients with invasive breast tumors without distant 
metastasis (pT1-4, pN0-3, M0). Stroma-high tumors were associated with a worse 
RFP (HR 1.97, 95% CI 1.47-2.64, p < 0.001) and overall survival (OS) (HR 1.50, 
95% CI 1.18-1.91, p = 0.001) analyzed with multivariate Cox regression analysis 
(table 1) (12). Vangangelt et al. analyzed the prognostic value of the TSR in a 
subset of the cohort of De Kruijf et al. in combination with the immune status of 
tumors. Determination of classical human leukocyte antigen (HLA) class I, HLA-E, 
HLA-G, natural killer cells and/or regulatory T cells in addition to the TSR showed 
to have an even stronger prognostic effect (16).
Dekker et al. investigated the prognostic value of the amount of stroma determined 
by visual eyeballing in 403 premenopausal node-negative breast cancer patients 
(cT1-3) (14). These patients were selected from the perioperative chemotherapy trial 
(POP trial, 10854) (48). This study supported the earlier finding of the TSR as an 
independent prognostic parameter for disease-free survival (DFS) (HR 1.85, 95% 
CI 1.33-2.59, p < 0.001) in favor of stroma-low tumors and borderline statistical 
significance for OS (HR 1.60, 95% CI 1.00-2.57, p = 0.050) (14).
Gujam et al. assessed the TSR on the H&E slides of 361 patients with invasive 
carcinoma of no special type (NST) (T1-3, N0->3, grade I-III) and subsequently 
found a correlation between stroma-high tumors and a poor 15-year cancer-specific 
survival (CSS) (HR 2.12, 95% CI 1.37-3.29, p = 0.001) in the multivariate survival 






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































stromal content with semi-automated point counting (46). They showed that a high 
tumor-stroma content in 118 women with ER-positive invasive breast tumors (grade 
I-III) was independently associated with a better OS and relapse-free survival 
(RFS) (95% CI 0.2-0.7, p = 0.008 and 95% CI 0.1-0.6, p = 0.006, respectively) (46).
After their first study, Downey and colleagues investigated the stromal content in 
45 patients with inflammatory breast cancer, a rare and aggressive form of breast 
cancer, using the semi-automated point counting method (47, 49). However, no
statistically significant difference was observed for this series (OS p = 0.53, DFS 
p = 0.66) (47).
Roeke et al. (T1-3, N0-2, grade I-III) validated by visual TSR assessment that a high 
stromal content was a prognostic factor for worse OS (HR 1.56, 95% CI 1.18-2.05, 
p = 0.002), distant-metastasis-free survival (DMFS) (HR 1.52, 95% CI 1.12-2.06, 
p = 0.008) and RFS (HR 1.35, 95% CI 1.01-1.81, p = 0.046) in their study of 737 
patients with primary operable invasive breast cancer (17). Unlike the work of 
Downey et al., patients with ER-positive stroma-high tumors were associated with 
a worse OS (HR 1.43, 95% CI 1.04-1.99, p = 0.030) (17).
THE TUMOR-STROMA RATIO IN TRIPLE-
NEGATIVE BREAST CANCER
For the applicability of the TSR as a prognostic parameter in TNBC patients, a 
study has been performed by Moorman et al. in 2012. They analyzed the TSR in 
a retrospective cohort study consisting of TNBC patients (pT1-4, pN0-3, grade 
I-III) (n = 124) (13). The amount of stroma was evaluated by visual eyeballing. 
Multivariate Cox regression analysis showed that the TSR was an independent 
prognostic factor for both RFP (HR 2.39, 95% CI 1.07-5.29, p = 0.033) and OS (HR 
3.00, 95% CI 1.08-8.32, p = 0.034), in favor of stroma-low tumors. The 5-year RFP 
and OS for patients with stroma-low tumors compared to stroma-high tumors were 
85% and 89% versus 45% and 65%, respectively (13).
Subgroup analysis of 82 TNBC in the cohort of De Kruijf et al. supported the 
results of Moorman and colleagues that patients with stroma-high tumors had a 
significant shorter RFP (HR 2.92, 95% CI 1.36-6.32, p = 0.006) and OS (HR 1.87, 




patients with stroma-low tumors were relapse-free compared to 56% of patients 
with stroma-high tumors (12).
Among the 403 patients in the cohort of Dekker and colleagues, 69 patients were 
diagnosed with TNBC. A separate analysis of patients with stroma-high TNBC 
validated a 2.71 greater risk of developing a recurrence compared to patients with 
stroma-low TNBC (DFS: HR 2.71, 95% CI 1.11-6.61, p = 0.028) (14).
However, in the study of Gujam et al., the percentage of tumor stroma was not 
found to be an independent prognostic factor for cancer-specific survival in 151 
TNBC patients (p = 0.151) (15). Likewise, Roeke et al. were not able to prove this 
correlation either (p = 0.221) (table 1) (17).
THE TUMOR-STROMA RATIO IN OTHER SUB-
GROUPS
De Kruijf et al., Gujam et al. and Roeke et al. described the role of the TSR in 
other subgroups. The results of De Kruijf et al. showed an independent prognostic 
value of the TSR in patients who only received local therapy (p < 0.001), adjuvant 
chemotherapy (p = 0.038) or adjuvant endocrine therapy (p = 0.024) (12). The 
latter was confirmed by Roeke et al. (p = 0.001) (17). The same results were seen 
in patients with TNBC who received only local therapy (p = 0.006).
In non-TNBC patients (p = 0.013), ER-positive patients (p = 0.030) and HER2-
negative tumors the TSR was also of independent prognostic value (12, 17). This 
was not the case for ER-negative and PR-negative breast tumors (17). In node-
negative tumors the TSR was also proved to be statistically significant for CSS and 
OS (p = 0.002 and p = 0.003, respectively) in two different studies (15, 17). Table 
2 presents a summary of these results.
DISCUSSION OF CURRENT LITERATURE
Extensive research has been performed to determine prognostic biomarkers 
for patient prognosis. Molecular tests, as the MammaPrint and Oncotype DX, 
have seemed to be valuable for the improvement of clinical decision making in 
early-stage breast cancer (7, 8). These tests will possibly be endorsed into routine 
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clinical practice to reduce the administration of adjuvant chemotherapy and prevent 
overtreatment (9). However, the disadvantages of the aforementioned molecular 
testing are the relatively high cost and the far more unknown influence of tumor 
heterogeneity. More specifically, intermingled non-tumor tissue may have a 
profound influence on the test results (50).
The TSR has shown to be of prognostic value in addition to the traditional 
prognostic markers which are implemented in standard clinical care, for example, 
TNM stage, receptor status and HER2 expression, in breast cancer with a robust 
inter-observer variability. In supplementary table 1 and supplementary table 2 the 
effect of the TSR in addition to the most important traditional prognostic markers 
is shown for the entire study population and triple-negative tumors, respectively.
So far, seven studies regarding the TSR have been performed in the field of breast 
cancer, of which five have shown a significant association between high tumor 
stroma content and a poor prognosis (12-15, 17). However, the results of both studies 
of Downey and colleagues were not in line with the other five (46, 47). As Downey 
et al. have determined the TSR with semi-automated point counting instead of 
visual eyeballing and have utilized different cut-off values in both studies, it may be 
concluded that a standardized estimation of the TSR is essential for a robust method, 
which can be applicable for patient management. The method of determining the 
TSR differed considerably, resulting in underestimating the heterogeneity (51). In 
contrast with previous studies, where the ultimate TSR category is based on the 
highest stroma rate in the sample, Downey and colleagues only scored an area of 
9 mm2 at the edge of the tumor (10, 46, 51, 52).
Although the difference in results can be attributed to this inconsistency, the 
different breast cancer subgroups regarding basic characteristics must be taken 
into consideration as well. The applicability in the subtypes, namely TNBC, 
ER-positive and inflammatory breast cancer, may differ and subsequently the 
individual relevance of the TSR has to be determined in breast cancer subgroups, 
as is previously performed by Roeke and colleagues (17). For example, in lobular 
carcinomas, the question is raised on how to determine which part is tumor induced 
stroma or tumor supportive stroma. This should be further determined in larger 
cohorts. Concerning TNBC, five studies have investigated this subgroup, of which 








































































































































































































































































































































































































































































































































































































































































studies are rather promising regarding the prognostic effect of the TSR (12-14). 
However, two other studies have not validated this prognostic effect despite the 
favorable results showed earlier. As mentioned by Roeke et al., this discordance 
could be contributed to the relatively low amount of stroma-high tumors in the 
TNBC subgroup (17). The similar reason could be the cause for the effect of the 
TSR in TNBC patients in the study of Gujam et al. (15). Another explanation could 
be that the histological type of TNBC plays a role.
Although different studies researched the prognostic value of TSR, little is 
known about the composition of the stroma. Even when using conventional light 
microscopy, vast differences in stromal morphology can be appreciated, which 
are surely reflective of enormous differences in stromal functionality. Molecular 
analyses have identified multiple molecular markers that are associated with 
varying degrees of stromal activation (53-55). These findings might allow us to 
distinguish activated, highly tumor-promoting stromal tissues from non-activated 
or only mildly active stromal tissues. Future studies investigating stromal activation 
might therefore solely focus on specific highly active subsets of stromal tissues 
as opposed to counting all stromal tissues equally, thereby further refining this 
parameter. For instance, as shown in a previous publication by the identification 
of PA28 as a marker of stromal activation (53).
Similarly, Ahn et al. investigated the stromal composition of breast cancer tissue. 
Besides the TSR, the dominant histological stroma type (collagen, fibroblast or 
lymphocytes) offers additional prognostic information. Five- and 10-year RFS rates 
were most favorable in the lymphocytic stroma type, followed by the fibroblast 
and collagen type. The latter was associated with the most aggressive tumor and 
consequently poorest prognosis (56). Interestingly, Ahn et al. observed a trend 
between TNBC and a predominantly lymphocytic stroma type, with 56.1% of 
the samples classified as ‘lymphocytic’. Considering TNBC has a relatively poor 
prognosis, the observed trend between TNBC and a predominantly lymphocytic 
stroma type, with a favorable prognosis, is striking. Leon-Ferre and colleagues 
showed similar results in early-stage TNBC in which the presence of low tumor-
infiltrating lymphocytes (TILs) contributes to a poor prognosis (57).
Considering the aforementioned generally promising prognostic effect in TNBC, 




Currently, adjuvant systemic chemotherapy is advocated for all patients that present 
with operable TNBC due to the aggressive nature of this tumor subgroup. Regarding 
TNBC, unlike other molecular subtypes, there is no Food and Drug Administration 
(FDA) approved targeted therapy yet. Forasmuch as both the aggressive nature of the 
subtype as the devoid of therapeutic options, supplementary research is necessary. 
For the development of curative therapeutics in TNBC, stromal targets have to be 
determined. Given the fact that TNBC predominantly consists of lymphocytic 
stroma, according to Ahn and colleagues, the possible target might lie within 
this stroma. The quantity of programmed death-ligand 1 (PD-L1), expressed on 
tumor cells, could be prognostic as well. Tomioka et al. have shown that low TILs, 
in combination with high PD-L1 expression, predicts an unfavorable prognosis. 
Within the abundant lymphocytic stroma in TNBC, PD-L1 could operate as a target 
for therapeutic options (58). Thus, in further research, in addition to a standardized 
estimation of the TSR, the biology or quality of the stroma should be taken into 
account as well, in both general breast cancer and especially in TNBC patients to 
clarify the paradox and subsequently to lay a foundation regarding targeted therapy.
Lastly, it should be noted that although previous studies demonstrated prognostic 
value in the past, these studies have always been performed as part of retrospective 
studies by researchers and pathologists with a specific interest in stromal tissues. 
Breast cancer is a heterogeneous disease, and for this reason, additional larger 
retrospective studies could add valuable information about the prognostic value of 
TSR in specific subgroups as well. Moreover, no prospective feasibility studies have 
been performed, and as such, it remains to be seen whether the broad application 
of this parameter would lead to reproducible test results. Current research efforts 
in this direction are, however, ongoing.
CONCLUSIONS
The current breast cancer prognostication schemes do not adequately predict patient 
prognosis. This leads to both over- and undertreatment with adjuvant chemotherapy. 
To better predict tumor biology and prevent unwarranted chemotherapy, additional 
prognostic parameters are necessary. The TSR can be a valuable biomarker for 
determining patient prognosis. The scoring can easily be performed by the 
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pathologist during routine pathological examination of H&E stained slides in less 
than a minute and without additional costs, as it is a quick, simple method with a 
high reproducibility. The field of tumor stroma provides promising perspectives, 
although standardization of the methodology is desired. There is a trend toward 
high stromal content and a poor prognosis, being most applicable in TNBC. The 
TSR, in this case, could be used to predict both disease progression and patient 
prognosis.
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The prognostic value of the tumor-
stroma ratio is most discriminative in 







The tumor-stroma ratio (TSR) was evaluated as a promising parameter for breast 
cancer prognostication in clinically relevant subgroups of patients.
Methods
The TSR was assessed on hematoxylin and eosin stained tissue slides of 1794 breast 
cancer patients from the Nottingham City Hospital. An independent second cohort 
of 737 patients from the Netherlands Cancer Institute-Antoni van Leeuwenhoek 
was used for evaluation.
Results
In the Nottingham Breast Cancer series, the TSR was an independent prognostic 
parameter for recurrence-free survival (RFS) (HR 1.35, 95% CI 1.10-1.66, 
p = 0.004). The interaction term was statistically significant for grade and triple-
negative status. Multivariate Cox regression analysis showed a more pronounced 
effect of the TSR for RFS in grade III tumors (HR 1.89, 95% CI 1.43-2.51, p < 0.001) 
and triple-negative tumors (HR 1.86, 95% CI 1.10-3.14, p = 0.020). Comparable 
hazard ratios and confidence intervals were observed for grade and triple-negative 
status in the ONCOPOOL study. The prognostic value of TSR was not modified by 
age, tumor size, histology, estrogen receptor status, progesterone receptor status, 
human epidermal growth factor receptor 2 status or lymph node status.
Conclusions
In conclusion, patients with a stroma-high tumor had a worse prognosis compared 
to patients with a stroma-low tumor. The prognostic value of the TSR was most 
discriminative in patients with grade III tumors and triple-negative tumors. The 
TSR was not modified by other clinically relevant parameters making it a potential 
factor to be included for improved risk stratification.
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INTRODUCTION
Breast cancer mortality rates are declining in most European countries due to 
early detection and improved treatment options (1). Optimizing risk stratification 
to prevent undertreatment and overtreatment by personalizing therapy is thereby 
essential.
In the last decade, the interplay of tumor cells and its microenvironment has gained 
increased interest. The tumor microenvironment, also known as tumor-associated 
stroma, consists of immune cells, fibroblasts, pericytes and endothelial cells in an 
extracellular matrix. The tumor microenvironment plays an active role in creating 
an environment that favors the tumor cells; increased motility of cells, suppression 
of the immune response, remodeling of the extracellular matrix and angiogenesis 
(2-6).
A promising prognostic parameter based on the tumor-associated stroma is the 
tumor-stroma ratio (TSR). The TSR reflects the amount of tumor stroma to the 
cancer cells, which is determined on routinely retrieved hematoxylin and eosin 
(H&E) stained tissue slides used for pathological assessment of surgically removed 
breast tissue. TSR assessment is easy, quick and without additional costs. Previous 
research demonstrated the prognostic value of the TSR in different types of invasive 
solid tumors, including breast cancer (7-32). Most of these studies validated a worse 
prognosis for patients with stroma-high tumors.
Breast cancer is a heterogeneous disease, which makes subgroup analysis essential. 
Kramer et al. reviewed literature published on the prognostic value of TSR in the 
general breast cancer population and different clinically important subgroups (33). 
Here, we set out to validate the effect of the TSR and further expand its utility in the 
clinically relevant subgroups for breast cancer prognostication. This is an essential 
step toward prospective validation and clinical implementation, such as the addition 






The Nottingham Breast Cancer series from Nottingham City Hospital (UK)
The study population consists of women of ≤70 years with primary invasive breast 
cancer without distant metastases, diagnosed and treated primarily with surgery 
in the Nottingham City Hospital between 1993 and 2002 (n = 1809). This cohort 
was retrospectively assembled. Patients were included if digital H&E slides of the 
primary breast tumors and follow-up data were available. Exclusion criteria were 
breast cancer in medical history and/or neo-adjuvant treatment.
The ONCOPOOL study from the Netherlands Cancer Institute-Antoni van Leeu-
wenhoek (the Netherlands)
A total of 737 women treated primarily with surgery for invasive non-metastasized 
breast cancer between 1990 and 1999, included in the ONCOPOOL study at The 
Netherlands Cancer Institute-Antoni van Leeuwenhoek hospital, were analyzed in 
this study. The included patients were part of the larger ONCOPOOL database of 
European primary breast cancer patients. Details on data management and patient 
selection were described previously (14, 34). Survival data, estrogen receptor 
(ER) status and progesterone receptor (PR) status are updated since the previous 
publication on tumor-stroma ratio according to the last publication using the 
ONCOPOOL study (14, 35).
All patient data were used in an anonymized manner and handled according to 
national ethical guidelines (“Code for Proper Secondary Use of Human Tissue”, 
Dutch Federation of Medical Scientific Societies”). The Nottingham Breast Cancer 
Series was approved by the Nottingham Research Ethics Committee 2 under the 
title “Development of molecular genetic classification of breast cancer”.
Assessment of the tumor-stroma ratio
In the Nottingham Breast Cancer series, the TSR was visually assessed on digital 
H&E stained slides of the primary breast tumor via CaseViewer 2.2 for Windows 
(3DHISTECH Ltd., Budapest, Hungary), a digital application for the evaluation 
of microscopic images. The original 4 µm routine H&E stained slides were 
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scanned into high-resolution (0.19 µm/pixel) digital images at 20x magnification 
using 3DHistech Panoramic 250 Flash II scanner (3DHISTECH Ltd., Budapest, 
Hungary). First, the whole tissue slide was visually evaluated for the orientation of 
the most stromal rich field. Second, the most stroma-abundant area was annotated 
using a circle with an area of 3.1 mm2. This microscopic field is comparable with 
the surface selected with a 10x objective of most light microscopes and corresponds 
with the magnification used previously (36). All slides were double scored in a 
blinded fashion (KV, WM). A third observer (DC) was consulted if consensus could 
not be reached. The tissue slide with the highest stroma percentage was decisive 
in cases where multiple slides were available per patient. Stromal areas suspected 
for post-biopsy effects were excluded from TSR assessment.
The TSR assessment on tumor tissue of patients included in the ONCOPOOL study 
was assessed using visual microscopy on conventional H&E slides (14).
The TSR was scored by the method of Mesker et al. in both cohorts (7). A 
percentage of ≤50% stroma was categorized as stroma-low and >50% stroma was 
categorized as stroma-high (supplementary figure 1).
Statistical analyses
Statistical analyses were performed using IBM SPSS statistics (version 23 for 
Windows). The recurrence-free survival (RFS), the primary endpoint, was defined 
as the time between the date of diagnosis and local, regional or distant recurrence. 
Patients who died without a recurrence were censored. Breast cancer-specific 
survival (BCSS), the secondary endpoint in the Nottingham Breast Cancer series, 
was defined as the time from date of diagnosis and breast cancer-specific death. 
The BCSS was not available for the ONCOPOOL study. Therefore, in this cohort, 
the overall survival (OS) was used as the second endpoint. The OS was defined as 
the time from diagnosis to death from any cause.
The X2 test was used to evaluate the difference between categorical variables in 
stroma-low and stroma-high groups. Fisher’s exact test was performed if less than 
five patients were included per category and Fisher-Freeman-Halton when the 
table was larger than 2x2. The Kaplan-Meier method and the log-rank test were 




The Cox regression model was used to perform univariate and multivariate analyses. 
In the multivariate Cox regression analysis of the Nottingham Breast Cancer series, 
the TSR and confounders were entered; age at diagnosis (continuous), grade (I,II 
or III), size (≤2 cm and >2 cm), histological type (invasive carcinoma of no special 
type (NST), lobular carcinoma, tubular carcinoma and others), ER status (negative 
or positive), PR status (negative or positive) and human epidermal growth factor 
receptor 2 (HER2) status (negative or positive). These analyses were also performed 
with triple-negative status as a variable instead of ER status, PR status and HER2 
status. Also, lymph node status was entered in the multivariate Cox regression in 
addition to standard confounders as described above, as lymph node status is not a 
confounder, but a clinically important parameter. A p-value <0.05 was considered 
as statistically significant. The univariate and multivariate Cox regression analyses 
of the ONCOPOOL study were also performed as described in the original report 
of Roeke et al., to check reproducibility. For the evaluation of the prognostic value 
of the TSR for clinically relevant subgroups, the interaction term was introduced in 




The Nottingham Breast Cancer series
A total of 2385 H&E slides of 1809 patients were assessed for the TSR. The slides 
of 15 (0.8%) patients were not eligible for TSR scoring due to the poor quality of 
the tissue. The Cohen’s kappa coefficient was 0.61 between two observers, which 
corresponds with a substantial to a good level of agreement. Due to the digital 
learning curve, slides with an incongruent value were individually assessed by the 
same observers for a second time (blinded from their first scores). Cohen’s kappa 
coefficient in the total cohort increased up to 0.87, which corresponds with an 
almost perfect level of agreement. The H&E slides of 37 patients were discussed 
with a third observer. A final agreement for the TSR was reached in all cases. A 
total of 1794 patients were suitable for statistical analysis. The median age at the 
time of diagnosis was 55 years (range 23–70 years), and the median follow-up 
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period was 11 years (range 0-18 years). Table 1 provides an overview of patient 
and tumor characteristics.
The ONCOPOOL study
The ONCOPOOL study included 737 women with breast cancer and was previously 
analyzed for the prognostic value of the TSR (14). The median age at inclusion was 
54 (range 23-71 years). The median follow-up was 12 years (range 0-24 years). 
Patient, tumor and treatment characteristics are shown in supplementary table 1.
TABLE 1. Overview of the stratification of age and tumor characteristics of the patients included in 
the Nottingham Breast Cancer Series.
Stroma-low Stroma-high
n n = 681 % n = 1113 %  p-value
Age (in years)
<40 144 71 10.4 73 6.6 0.006
40-<50 385 151 22.2 234 21.0
50-<60 636 247 36.3 389 35.0
≥60 628 212 31.1 416 37.4
Missing 1 0 0.0 1 0.1
Tumor size (in cm’s)
≤2 1146 505 74.2 641 57.6 <0.001
>2-<5 625 169 24.8 456 41.0
≥5 21 6 0.9 15 1.3
Missing 2 1 0.1 1 0.1
Lymph node involvement
No 1127 452 66.4 675 60.6 0.015
Yes 664 227 33.3 437 39.3
Missing 3 2 0.3 1 0.1
Grade
I 279 105 15.4 174 15.6 0.606
II 733 272 39.9 461 41.4
III 781 303 44.5 478 42.9
Missing 1 1 0.1 0 0
Histological type
Invasive carcinoma of 






n n = 681 % n = 1113 %  p-value
Lobular carcinoma 155 53 7.8 102 9.2
Tubular carcinoma 275 90 13.2 185 16.6
Others 235 88 12.9 147 13.2
ER status
Negative 331 151 22.2 180 16.2 0.001
Positive 1463 530 77.8 933 83.8
PR status
Negative 708 282 41.4 426 38.3 0.262
Positive 1067 390 57.3 677 60.8
Missing 19 9 1.3 10 0.9
HER2 status
Negative 1573 594 87.2 979 88.0 0.645
Positive 221 87 12.8 134 12.0
Triple-negative tumors
No 1546 560 82.2 986 88.5 0.001
Yes 235 115 16.9 120 10.8
Missing 13 6 0.9 7 0.6
Chemotherapy
No 699 255 37.4 444 39.9 0.577
Yes 292 115 16.9 177 15.9
Missing 803 311 45.7 492 44.2
Hormonal therapy
No 455 182 26.7 273 24.5 0.112
Yes 778 274 40.2 504 45.3
Missing 561 225 33.0 336 30.2
Abbreviations: ER = estrogen receptor, HER2 = human epidermal growth factor receptor 2, 
NST = no special type, PR = progesterone receptor
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The prognostic value of the TSR
In the total study population of the Nottingham Breast Cancer series, 681 (38%) 
patients were categorized in the stroma-low group and 1113 (62%) patients in the 
stroma-high group. Table 1 shows the statistically significant differences between 
both stroma categories. Age, tumor size, lymph node involvement, ER status and 
triple-negative tumors were significantly different between both stromal categories.
The Kaplan-Meier analysis and the log-rank test for RFS showed a statistically 
significant different outcome between patients with a stroma-low and stroma-high 
tumor in favor of patients with stroma-low tumors (supplementary figure 2). The 
TSR was an independent prognostic parameter in favor of patients with stroma-low 
tumors for both RFS and BCSS when adjusted for different sets of confounders 
(table 2 and table 3)
Since the ONCOPOOL study was updated, the prognostic value of the TSR was 
evaluated again. The analyses showed that patients with a high stromal content 
tumor had a worse survival in the total cohort as well as in subgroups. The results 
from the multivariate Cox regression analysis of the updated database were 
comparable with those of the original observations; RFS HR 1.35, 95% CI 1.01-1.79, 
p = 0.040 versus HR 1.35, 95% CI 1.01-1.81, p = 0.046 and OS HR 1.46, 95% CI 
1.13-1.88, p = 0.003 versus HR 1.56, 95% CI 1.18-2.05, p = 0.002, respectively (data 
not shown). When the TSR was adjusted confounders, the OS showed a statistically 
significant difference in favor of stroma-low tumors. The results for the RFS were 











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































TABLE 3. Results of the independent prognostic value of the tumor-stroma ratio adjusted 
for only confounders, confounders including triple-negative status or confounders combined 
with lymph node status, calculated with multivariate Cox regression analysis in the 
Nottingham Breast Cancer series.
Recurrence-free survival Breast cancer-specific 
survival
Confounders HR 1.35, 95% CI 1.10-1.66,
p = 0.004




HR 1.34, 95% CI 1.09-1.64,
p = 0.006
HR 1.47, 95% CI 1.15-1.90, 
p = 0.002
Confounders combined 
with lymph node status
HR 1.35, 95% CI 1.10-1.66,
p = 0.004
HR 1.51, 95% CI 1.17-1.94,
p = 0.002
The TSR stratified by clinically important subgroups
In the Cox regression analysis, the interaction term was introduced to evaluate the 
prognostic effect in different clinically important subgroups.
In the Nottingham Breast Cancer series, the interaction term showed a statistically 
significant p-value for grade (p < 0.001 and p = 0.002) and triple-negative status 
(p = 0.040 and p = 0.026) for RFS and BCSS, respectively. No statistically 
significant results for RFS and BCSS were observed if stratified for age, tumor 
size, histology, ER status, PR status, HER2 status and lymph node status. The 
prognostic value of the TSR calculated by multivariate Cox regression analysis 
showed the most discriminative effect of the TSR in grade III tumors compared to 
grade I and grade II tumors, and in triple-negative tumors compared to nontriple-
negative tumors, for RFS and BCSS (table 4). Kaplan-Meier analysis and log-rank 
test for RFS of the TSR stratified by grade and triple-negative status showed a 
statistically significant difference between subgroups (figure 1 and figure 2)
The ONCOPOOL study was used to validate the survival effects in grade III tumors 
and triple-negative tumors. The interaction term for grade (p = 0.122) and triple-
negative status (p = 0.343) was not significant for RFS. The HRs of the prognostic 
effect of the TSR for RFS were most discriminative in grade III tumors compared 
to grade I and grade II. If stratified by triple-negative status, the HR of the TSR in 
nontriple-negative tumors was lower compared to triple-negative tumors, but this 
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was not statistically significant. The interaction term was not statistically significant 
if stratified by age, tumor size, histology, ER status, PR status, HER2 status and 
lymph node status (supplementary table 4)
TABLE 4. Results of the tumor-stroma ratio stratified by clinically important prognostic 
parameters in the Nottingham Breast Cancer series and the multivariate Cox regression 







Age p = 0.881 p = 0.874
Tumor size p = 0.422 p = 0.209
Grade p < 0.001 p = 0.002
Grade I HR 1.16, 95% CI 0.58-2.29, p = 0.670
HR 6.34, 95% CI 0.81-49.95, 
p = 0.079
Grade II HR 0.78, 95% CI 0.55-1.10, p = 0.152
HR 0.83, 95% CI 0.54-1.30,
p = 0.422
Grade III HR 1.89, 95% CI 1.43-2.51, p < 0.001
HR 1.86, 95% CI 1.35-2.57,
p < 0.001
Histological 
type p = 0.684 p = 0.951
ER status p = 0.088 p = 0.101
PR status p = 0.861 p = 0.532
HER2 status p = 0.205 p = 0.851
Triple-negative 
status p = 0.040 p = 0.026
Nontriple-
negative status
HR 1.21, 95% CI 0.97-1.51, 
p = 0.095




HR 1.86, 95% CI 1.10-3.14, 
p = 0.020
HR 2.24, 95% CI 1.24-4.07,
p = 0.008
Lymph node 
status p = 0.995 p = 0.432
Abbreviations: ER = estrogen receptor, HER2 = human epidermal growth factor receptor 




FIGURE 1. Kaplan-Meier analysis for recurrence-free survival of patients included in the 







0 5 10 15 20
Numbers at risk
Stroma-low/grade I 105 96 66 14 3
Stroma-high/grade I 174 154 113 15 3
Stroma-low/grade II 272 229 143 22 3
Stroma-high/grade II 461 385 255 49 7
Stroma-low/grade III 303 239 162 34 4
Stroma-high/grade III 478 320 197 42 5
Stroma-low and grade I
Stroma-high and grade I
Stroma-low and grade II
Stroma-high and grade II
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In our study, we evaluated the prognostic value of the TSR in, to the best of our 
knowledge, the largest cohort published on the prognostic value of the TSR in 
breast cancer. The number of patients offered the opportunity to perform analyses 
of clinically relevant subgroups for breast cancer prognostication and treatment.
First, patients with a stroma-high tumor had a worse prognosis compared to patients 
with a stroma-low tumor. Second, the results of the Nottingham Breast Cancer 
series showed that the prognostic effect of the TSR was most discriminative in 
grade III tumors, compared to grade I and grade II tumors, and in triple-negative 
tumors, compared to nontriple-negative tumors. In the ONCOPOOL study, the HRs
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FIGURE 2. Kaplan-Meier analysis for recurrence-free survival of patients included in 
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Stroma-low/non-triple negative 560 469 306 52 9
Stroma-high/non-triple negative 986 781 505 94 13
Stroma-low/triple negative 115 91 63 17 1
























and confidence intervals of the TSR stratified by grade and triple-negative status 
were comparable with the Nottingham Breast Cancer series. The interaction term 
showed no statistically significant effect for RFS if stratified by grade or triple-
negative status. A possible explanation of the lack of statistical significance is the 
moderate number of events.
Third, the prognostic effect of the TSR was not modified by age, tumor size, 
histology, ER status, PR status, HER2 status and lymph node status. This means 
that the prognostic value of the TSR in these clinically relevant subgroups does not 




No former published literature has evaluated the prognostic value of the TSR 
by introducing the interaction term. Therefore, the results are not completely 
comparable. However, previous research showed higher HRs for the TSR in patients 
with triple-negative tumors as overviewed by Kramer et al. (33). The effect of the 
TSR stratified by grade has not been previously described.
The next step toward the clinical implementation of the TSR is to investigate the 
discriminating prognostic value of the TSR additional to the commonly used 
online PREDICT tool, which helps oncologists and patients in a shared decision-
making toward personalized therapy (37, 38). Therefore, retrospective data will 
be analyzed and a prospective study such as the UNITED (Uniform Noting for 
International application of the Tumor-stroma ratios as Easy Diagnostic Tool) study 
needs to be performed (39). The UNITED study is a prospective international 
multicenter study initiated by our research group. The study aim is to validate and 
prepare the TSR for implementation in standard clinical care in patients with colon 
cancer. Implementation of TSR assessment in standard clinical care has advantages 
compared to other potential biomarkers as this method is easy to perform, takes less 
than two minutes and requires no additional costs. Therefore, a comparable study 
for breast cancer would be desirable in the next step toward clinical implementation. 
Inter-observer and intra-observer reliability of the TSR assessment on digital slides 
in colon cancer is also evaluated in the UNITED study. The TSR assessment is 
explained to pathologists and residents via e-learning and test sets.
The Nottingham Breast Cancer series is the first study in which the TSR is digitally 
assessed on breast cancer tissue by the method of Mesker et al. (7). For the digital 
assessment, a field of 3.1 mm2 was used for final TSR scoring, which corresponds 
with conventional light microscopy used in our previous research. Van Pelt et al. 
described that the diameters of the different conventional light microscopes are 
between 2.54 and 3.80 mm2. However, this has not led to any major differences 
in the final score (36). One hundred percent of the slides were double scored in a 
blinded fashion by two observers (KV,WM), instead of the customary 30% double 
scoring, because of the possible learning curve of scoring digitally for the first 
time. The Cohen’s kappa coefficient increased from 0.61 at first assessment to 0.87 
in the second assessment of the slides with an incongruent value at the first time. 
In our opinion, observers who perform digital TSR assessment for the first time 
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need to be aware of a learning curve. If this stage is passed, the TSR scoring on 
digital slides seems to be reliable and therefore gives a good perspective for further 
digital assessment.
Furthermore, the intra-tumoral stroma contains valuable prognostic information 
and may, therefore, be an important source for the development of new stroma based 
therapeutic agents. A major component of the tumor-associated stroma and thus a 
promising therapeutic target are CAFs. At the moment, CAFs are still difficult to 
target due to the lack of specific cell surface targets, as they are heterogenous in 
phenotype and function. An important recent finding is the identification of CD10 
and GPR77 as surface markers on CAFs in breast cancer. CD10+GPR77+ CAFs are 
predictive for response to chemotherapy and patient survival, particularly in breast 
tumors with a high grade (40). The authors showed that the disease-free survival of 
breast cancer patients with a high CD10+GPR77+ CAF infiltration was significantly 
shorter. The disease-free survival of patients with grade I and grade II tumors were 
independent of CD10+GPR77+ CAF infiltration (6). These results are interesting 
as we found that the prognostic value of the TSR is most discriminative in grade 
III tumors compared with grade I and grade II tumors. Whether CAF subtypes 
differ between stroma-low and stroma-high tumors is not known at this moment 
and requires further research.
Moreover, Ahn and colleagues concluded that, especially in patients with grade III 
tumors, the dominant stroma type was an independent risk factor for disease-free 
survival in favor for patients with lymphocyte dominant stroma (41). Therefore, 
evaluation of the stromal composition would be interesting, for instance by 
dividing the stromal compartment in dominant stroma type; collagen, fibroblast 
or lymphocyte.
Advantages of this study are the large cohort size and long follow-up period. A 
limitation of this study is the time period in which patients are included and as a 
consequence the changes in treatment modalities. In the studied patient groups, 
proportionally less patients received hormonal therapy than in current treatments. 
However, previously published research, including the ONCOPOOL study, showed 
that the TSR was of prognostic value in patients with hormone receptor-positive 
tumors who received hormonal therapy (9,14). This may suggest that the prognostic 




the introduction of Trastuzumab has positively influenced clinical outcome. 
Therefore, a large more recent retrospective study, in which the change in treatment 
modalities and a decent follow-up period are considered, and/or a prospective 
cohort study should be performed to validate the TSR in the next step toward 
clinical implementation.
CONCLUSIONS
The results showed that the prognostic effect of the TSR is most discriminative in 
grade III tumors, compared to grade I and grade II tumors, and in triple-negative 
tumors, compared to nontriple-negative tumors. Furthermore, the prognostic value 
of the TSR was not modified by age, tumor size, histology, ER status, PR status, 
HER2 status and lymph node status. This makes this parameter a potential factor 
to be included to improve risk stratification. Validating the TSR in a prospective 
study could further improve clinical decision making using the PREDICT tool.
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SUPPLEMENTARY DATA
SUPPLEMENTARY FIGURE 1. Representative tissue selection for tumor-stroma ratio 
assessment.
a. Stroma-low b. Stroma-high.
a. b.
SUPPLEMENTARY FIGURE 2. Kaplan-Meier analysis for recurrence-free survival of 




SUPPLEMENTARY TABLE 1. Overview of the stratification of age, tumor 
characteristics and treatment options of patients included in the ONCOPOOL study.
Stroma-low Stroma-high
n n = 454 % n = 283 %  p-value
Age (in years)
<40 63 49 10.8 14 4.9 0.012
40-49 206 134 29.5 72 25.4
50-59 259 147 32.4 112 39.6





621 386 85.0 235 83.0 0.484
Lobular 
carcinoma
69 38 8.4 31 11.0
Tubular 
carcinoma
32 22 4.8 10 3.5
Others 15 8 1.8 7 2.5
Grade
I 159 101 22.2 58 20.5 0.274
II 255 146 32.2 109 38.5
III 216 142 31.3 74 26.1
Missing 107 65 14.3 42 14.8
Tumor size (in cm’s)
≤2 479 314 69.2 165 58.3 0.005
>2-≤5 252 135 29.7 117 41.3
>5 6 5 1.1 1 0.4
Nodal status
Negative 416 257 56.6 159 56.2 0.145
Positive 315 191 42.1 124 43.8
Missing 6 6 1.3 0 0
ER status
Negative 127 87 19.2 40 14.1 0.142
Positive 606 365 80.4 241 85.2
Missing 4 2 0.4 2 0.7
PR status
Negative 234 149 32.8 85 30.0 0.442
Positive 496 302 66.5 194 68.6
Missing 7 3 0.7 4 1.4
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SUPPLEMENTARY TABLE 1. Continued.
Stroma-low Stroma-high
n n = 454 % n = 283 %  p-value
HER2 status
Negative 573 357 78.6 216 76.3 0.462
Positive 151 91 20.0 60 21.2
Missing 13 6 1.3 7 2.5
Chemotherapy
No 573 346 76.2 227 80.2 0.204
Yes 164 108 23.8 56 19.8
Hormonal therapy
No 369 229 50.4 140 49.5 0.798
Yes 368 225 49.6 143 50.5
Abbreviations: ER = estrogen receptor, HER2 = human epidermal growth factor receptor 
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































SUPPLEMENTARY TABLE 3. Results of the independent prognostic value of the 
tumor-stroma ratio adjusted for confounders, confounders including triple-negative status 
and confounders combined with lymph node status, calculated with multivariate Cox 
regression analysis in the ONCOPOOL study.
Recurrence-free survival Overall survival
Confounders HR 1.30, 95% CI 0.96-1.76, p = 0.085




HR 1.30, 95% CI 0.96-1.75, 
p = 0.091
HR 1.34, 95% CI 1.02-1.74, 
p = 0.033
Confounders combined 
with lymph node status
HR 1.28, 95% CI 0.95-1.73, 
p = 0.112
HR 1.33, 95% CI 1.02-1.74, 
p = 0.037
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SUPPLEMENTARY TABLE 4. Results of the tumor-stroma ratio stratified by clinically 
important prognostic parameters in the ONCOPOOL study and the multivariate Cox 
regression analysis per clinically relevant subgroup with a statistically significant difference 
in the Nottingham Breast Cancer series.
TSR stratified 
by group
Subgroups Recurrence-free survival Overall survival
Age p = 0.496 p = 0.840
Tumor size p = 0.816 p = 0.823
Grade p = 0.122 p = 0.414
Grade I HR 0.92, 95% CI 0.39-2.35,
p = 0.992
HR 0.83, 95% CI 0.38-1.81, 
p = 0.631
Grade II HR 1.06, 95% CI 0.66-1.70,
p = 0.806
HR 1.30, 95% CI 0.83-2.02, 
p = 0.257
Grade III HR 1.86, 95% CI 1.18-2.93,
p = 0.008
HR 1.61, 95% CI 1.08-2.41, 
p = 0.020
Histological type p = 0.838 p = 0.620
ER status p = 0.445 p = 0.222
PR status p = 0.982 p = 0.387
HER2 status p = 0.646 p = 0.910
Triple-negative 
status
p = 0.343 p = 0.255
Nontriple-
negative status
HR 1.25, 95% CI 0.91-1.73,
p = 0.176




HR 1.54, 95% CI 0.64-3.66,
p = 0.333




p = 0.423 p = 0.097
Abbreviations: ER = estrogen receptor, HER2 = human epidermal growth factor 
receptor, PR = progesterone receptor
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The intra-tumoral stroma in patients 






The tumor microenvironment in older patients is subject to changes. The tumor-
stroma ratio (TSR) was evaluated in order to estimate the amount of intra-tumoral 
stroma and to evaluate the prognostic value of the TSR in older patients with breast 
cancer (≥70 years).
Methods
Two retrospective cohorts, the FOCUS study (n = 619) and the Nottingham Breast 
Cancer series (n = 1793), were used for assessment of the TSR on hematoxylin and 
eosin stained tissue slides.
Results
The intra-tumoral stroma increases with age in the FOCUS study and the 
Nottingham Breast Cancer series (B 0.031, 95% CI 0.006-0.057, p = 0.016 and 
B 0.034, 95% CI 0.015-0.054, p < 0.001, respectively). Fifty-one percent of the 
patients from the Nottingham Breast Cancer series <40 years had a stroma-high 
tumor compared to 73% of the patients of ≥90 years from the FOCUS study. The 
TSR did not validate as an independent prognostic parameter in patients ≥70 years.
Conclusions
The intra-tumoral stroma increases with age. This might be the result of an 
activated tumor microenvironment. The TSR did not validate as an independent 
prognostic parameter in patients ≥70 years in contrast to young women with breast 
cancer as published previously.
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INTRODUCTION
Breast cancer is the leading malignancy in European women (1). A major risk factor 
for breast cancer development is aging (2).
In the last decade, the tumor microenvironment has gained interest in unravelling 
cancer development and cancer progression, but also as a source for new therapeutic 
targets and prognostic parameters. The tumor microenvironment, i.e. tumor stroma, 
consists of a variety of structures and cells located in the extracellular matrix, 
such as immune cells, fibroblasts and endothelial cells. Various processes in 
the tumor microenvironment are involved in tumor progression by influencing 
the proliferation of cancer cells, the epithelial-mesenchymal transition, tumor 
metabolism and dissemination capabilities (3). Epidemiological and clinico-
pathological characteristics are different in older patients with breast cancer 
compared to their younger counterparts (4-7). The biology of breast cancer is 
age-dependent in which alterations in extracellular matrix and products secreted 
by senescent fibroblasts are thought to promote late-onset breast tumorigenesis, 
however the extent is still unknown (8). Research into the molecular profile of 
older patients with triple-negative breast cancer showed a different stromal 
microenvironment favorable for tumorigenesis, in which senescence-associated 
secretory profile and autophagy are important aberrant stromal features induced 
with increasing age (9).
A widely researched prognostic marker based on the tumor-microenvironment is 
the tumor-stroma ratio (TSR). The TSR reflects the ratio between tumor cells and 
stromal cells and is visually assessed with conventional light microscopy. Previous 
studies have shown that the TSR is a valuable prognosticator for breast cancer 
patients, whereby tumors with a high stromal content are associated with a poor 
clinical outcome (10-18). This effect was observed and validated in the overall 
group of breast cancer patients and clinically relevant subgroups (18).
In the current literature, older patients are often defined as patients of 70 years and 
older (19). In older patients with breast cancer, better risk stratification is desirable. 
Whilst breast cancer mortality in the total group of patients with breast cancer has 
decreased over the last decade, this decrease is lower or absent in older patients. 
This leads to an increased survival gap between older and younger patients with 




have a more favorable biology compared to younger females. Improvement of 
prognostic tools is needed for more accurate prediction of prognosis in the older 
breast cancer patient, considering that only very few older patients with breast 
cancer aged over 70 years receive chemotherapy (24). More accurate stratification 
of disease aggressiveness could contribute to shared-decision making on the extent 
of adjuvant therapy. This may minimize the risk of undertreatment which may 
contribute in the survival gap between younger and older patients with breast 
cancer. Although extensive research in population-based studies showed that the 
TSR is an important prognosticator in women with breast cancer, none of these 
studies have focused on its significance in the older female population.
Therefore, the aims of this study were (1) to investigate the amount of intra-tumoral 
stroma by the assessment of the TSR in older patients with breast cancer and (2) to 
evaluate the prognostic value of the TSR in women diagnosed with breast cancer 
at the age of 70 years or older.
MATERIAL AND METHODS
Study population
This study included two databases with retrospectively collected clinical data from 
women diagnosed with breast cancer.
The FOCUS study
The FOCUS study consisted of a population-based cohort of women aged 65 years 
and older, who were diagnosed with breast cancer (n = 3672) between 1997 and 
2004 in Comprehensive Cancer Centre Region West (The Netherlands). Women 
with a history of cancer or in situ tumors, neoadjuvant therapy, distant metastasis 
at time of diagnosis, age under 70 years or with no available tumor tissue were 
excluded. In total, 1577 women were suitable for analysis. This cohort was used to 
answer both study aims, the evaluation of the amount of intra-tumoral stroma and 
the prognostic value of the TSR in the older women with breast cancer.
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The Nottingham Breast Cancer Series
The Nottingham Breast Cancer Series (n = 1809) is a cohort of women ≤70 years 
of age presenting with primary invasive breast cancer without distant metastasis 
and primarily treated with surgery in Nottingham City Hospital between 1993 and 
2002. Patients were included if hematoxylin and eosin (H&E) stained tissue slides 
and clinical information (patients and tumor characteristics and survival data) were 
available. This study was used for the evaluation of the amount of intra-tumoral 
stroma with the increase of age.
For standard clinical care all resected tumors were assessed by a pathologist, 
according to the currently applied pathological standards. The clinical data from 
the Nottingham Breast Cancer series were anonymized and the study was approved 
by the Nottingham Research Ethics Committee 2 under the title ‘Development of 
a molecular genetic classification of breast cancer’. All samples from the FOCUS 
study were also anonymized and data were handled according to national ethical 
guidelines (“Code for Proper Secondary Use of Human Tissue”, Dutch Federation 
of Medical Scientific Societies”).
Tumor-stroma ratio assessment
The tissues slides from the FOCUS study were assessed for the TSR by visual 
eyeballing with a conventional light microscope on standard H&E stained tissue 
slides, as previously described by our group (10, 25). The most stroma-rich area 
on the slide was selected with a 5x objective. A 10x objective was used to select 
the final most stroma-abundant area. The H&E slides from the Nottingham 
Breast Cancer series were digitally assessed via CaseViewer 2.2 for Windows (3D 
HISTECH Ltd.). The original H&E slides were scanned with a 20x magnification 
using 3D Histech Panoramic 250 Flash II (3DHISTECH Ltd., Budapest, Hungary). 
The most stroma-abundant area was selected and in the most stroma-rich field a 
circle with an area of 3.1 mm2 was annotated. This area corresponded with the 
magnification used in our previously published research (26). The next steps in the 
assessment of the TSR on digital images and conventional images were performed 
in the same manner. The percentage of stromal cells compared to tumor cells in the 




cells at all borders of the image field. Stromal areas with post-biopsy effects were 
avoided. Finally, the determined percentages were divided into two categories; 
stroma-low (≤50% stroma) and stroma-high (>50% stroma) (figure 1). The tissues 
slides were scored double in a blinded fashion. If no consensus could be reached 
between the two observers a third observer was consulted. Consensus could be 
reached in all cases.
FIGURE 1. Representative example of tumor-stroma ratio assessment                                                     
a. Stroma-high tumor b. Stroma-low tumor.
Statistical analyses
For statistical analyses, SPSS statistics version 23.0 (SPSS Inc., IBM Company 
Chicago, IL, USA) was used. Relative survival analyses were performed with 
STATA SE software version 12 (StataCorp, College Station, TX). A Cohen’s kappa 
was calculated for the evaluation of inter-observer agreement. A value above 0.6 
was considered as a good level of agreement. To evaluate the difference of patient 
characteristics between women with stroma-low or stroma-high tumors, the χ2 test 
was used in case of categorical variables. The distribution of numerical variables 
was tested with the Shapiro-Wilk test. Non-parametric continuous variables 
were evaluated using the Mann-Whitney U test. Linear regression analysis was 
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performed to investigate the association between age (continue) and the intra-
tumoral stroma in percentage (increments of 10%). The linear regression analysis 
was adjusted for tumor size, histology, estrogen receptor (ER) status, progesterone 
receptor (PR) status, human epidermal growth factor 2 (HER2) status, triple-
negative (TN) status and grade, as these parameters might influence the amount 
of intra-tumoral stroma.
The primary endpoint was recurrence-free period (RFP). The definition for RFP 
was time from diagnosis to local, regional or distant recurrence or contralateral 
breast cancer. Censoring was applied at the last date at which patients were known 
to be recurrence-free and alive. The secondary endpoint was relative survival (RS). 
This was defined as the observed overall survival (OS) among included patients 
divided by the expected survival in the general population. Groups were matched 
by sex, age and calendar year. This analysis was applied according to the Ederer 
II method with use of the ‘strs’ command in STATA. A relative survival rate of 
less than 100% at 10 years after diagnosis means that the survival of patients in the 
study is lower than expected when compared to survival of the general population. 
The relative survival data were calculated at 10-year follow-up. The relative excess 
risk (RER) of death was estimated using a multivariable generalized linear model 
with a Poisson distribution, based on collapsed relative survival data, using exact 
survival times. To assess the differences in RFP for our parameter of interest, the 
Kaplan-Meier curves were compared using the log-rank test. This test was also 
used for analyzing different TSR cut-off values, other than the normally used 50% 
(i.e. ≤50% stroma is categorized as stroma-low and >50% stroma is categorized as 
stroma-high). A p-value lower than 0.05 was considered statistically significant for 
all analyses. Cox regression analyses were used to calculate the prognostic value 
of the TSR (univariate and multivariate). The TSR was corrected for clinically 
important confounders. The interaction term was introduced to evaluate the 
prognostic value of the TSR stratified by confounders. Power analysis showed that 
at least 618 patients of the FOCUS study must be analyzed to reach a power of 0.80 







In total, 1577 women included in the FOCUS study were eligible for inclusion. 
Based on power calculation, 627 patients were selected via computer randomization 
(minimum of 618 patients). The included (n = 627) and excluded (n = 950) patients 
were compared for age, tumor grade, histological type, T-stage, N-stage, hormone 
receptor status, HER2 status, type of operation, radiotherapy, chemotherapy and 
hormonal therapy. Between these two groups, only hormonal therapy showed to be 
statistically significant different (p = 0.003). In the included group, more patients 
were treated with hormonal therapy. However, hormonal therapy has no association 
with outcome (HR 1.01, 95% CI 0.66-1.54, p = 0.975). The median age of the 
excluded patients was 78 and the median age of the included women was 79 at 
time of diagnosis. Eight slides were not suitable for TSR assessment due to poor 
quality of the staining.
The characteristics of the selected patients are described in table 1. Cohen’s kappa 
inter-observer agreement was 0.77 (33% of slides were scored in a double-blinded 
fashion).
TABLE 1. Statistically significant difference between stroma-low and stroma-high tumors 
in the FOCUS study.
Stroma-low Stroma-high
n n = 204 % n = 415 % p-value
Age (in years)
619 79 (mean) 80 (mean) 0.020
Grade
I 82 31 22.0 51 17.3 0.126
II 198 69 48.9 129 43.9





471 148 72.5 323 77.8 0.171
Lobular 
carcinoma
65 28 13.7 37 8.9
Other 83 28 13.7 55 13.3
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TABLE 1. Continued.
Stroma-low Stroma-high
n n = 204 % n = 415 % p-value
Tumor size
pT1 254 96 47.1 158 38.1 0.014
pT2 286 92 45.1 194 46.7
pT3/4 79 16 7.8 63 15.2
Tumor involvement in the lymph nodes
Negative 353 134 66.3 219 54.2 0.004
Positive 253 68 33.7 185 45.8
ER status
Negative 95 33 18.9 62 16.9 0.574
Positive 447 142 81.1 305 83.1
PR status
Negative 195 64 38.8 131 37.8 0.822
Positive 317 101 61.2 216 62.2
HER2 status
Negative 484 151 76.3 333 82.0 0.096
Positive 120 47 23.7 73 18.0
Type of surgery
BCS 181 68 33.3 113 27.2 0.117
MST 438 136 66.7 302 72.8
Radiotherapy
No 366 121 59.3 245 59.0 0.947
Yes 253 83 40.7 170 41.0
Chemotherapy
No 602 199 97.5 403 97.1 0.753
Yes 17 5 2.5 12 2.9
Hormonal therapy
No 303 112 54.9 191 46.0 0.038
Yes 316 92 45.1 224 54.0
Abbreviations: BCS = breast conserving surgery, ER = estrogen receptor, 
HER2 = human epidermal growth factor receptor 2, MST = mastectomy, NST = no 





The Nottingham Breast Cancer Series
An external cohort of primary breast cancer patients diagnosed in Nottingham 
City Hospital was used for the evaluation of the TSR in order to investigate 
alterations in the amount of intra-tumoral stroma. Due to bad quality of the tissue, 
15 patients were excluded (0.8%), and one patient was excluded because clinical 
information regarding patients age was unknown. Finally, 1793 patients were used 
in the analyses. The mean age was 55. An overview of patient characteristics, 
tumor characteristics and treatment is shown in table 2. All slides were assessed 
by two observers. If no consensus could be reached a third observer was consulted. 
Consensus was reached in all cases.
Alterations in stromal amount with the increase of age
For the patients in the FOCUS study (n = 619), the Mann-Whitney U test showed 
a significant association between age and the TSR (p = 0.020). By evaluating the 
TSR, the results showed a higher amount of intra-tumoral stroma with the increase 
of age (B 0.025, 95% CI 0.004-0.045, p = 0.018). In the group of patients between 
70 and <75 years of age, 63% of the tumors were assessed as stroma-high compared 
to 73% of the tumors in patients aged 90 years or older (figure 2a).
To evaluate this age effect in an independent cohort, the Nottingham Breast Cancer 
Series (n = 1793), consisting of breast cancer patients of ≤70 years of age, was 
assessed. The Mann-Whitney U test showed a significant association between age 
and TSR (p = 0.003). In this patient cohort, the evaluation of the TSR showed that 
the amount of intra-tumoral stroma also increases with age (B 0.033, 95% CI 0.014-
0.053, p = 0.001). Of the patients under the age of 40, 51% was scored as stroma-
high compared to 66% of patients between 65 and 70 years of age (figure 2b).
Linear regression was adjusted for tumor size, histology, ER status, PR status, 
HER2 status, TN status and grade in the FOCUS study and the Nottingham Breast 
Cancer Series (B 0.031, 95% CI 0.006-0.057, p = 0.016 and B 0.034, 95% CI 0.015-
0.054, p < 0.001, respectively). These results showed that the association between 
the amount of intra-tumoral stroma and age remained statistically significant after 
adjustment of pathological tumor-based characteristics.
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TABLE 2. Statistically significant difference between stroma-low and stroma-high tumors 
in the Nottingham Breast Cancer series.
Stroma-low Stroma-high
n  n = 681 % n = 1113 % p-value
Age (in years)
1793 54 (mean) 55 (mean) 0.003
Grade
I 279 105 15.4 174 15.6 0.779
II 733 272 40.0 461 41.5
III 780 303 44.6 477 42.9
Histological type
Invasive carcinoma of NST 1128 450 66.1 678 61.0 0.114
Lobular carcinoma 155 53 7.8 102 9.2
Tubular carcinoma 275 90 13.2 185 16.6
Others 235 88 12.9 147 13.2
Tumor size
T1 1146 505 74.3 641 57.7 <0.001
T2 624 169 24.9 455 41.0
T3 21 6 0.9 15 1.4
Tumor involvement in lymph nodes
Negative 1127 452 66.6 675 60.8 0.013
Positive 663 227 33.4 436 39.2
ER status
Negative 331 151 22.2 180 16.2 0.002
Positive 1462 530 77.8 932 83.8
PR status
Negative 708 282 42.0 426 38.7 0.168
Positive 1066 390 58.0 676 61.3
HER2 status
Negative 1572 594 87.2 978 87.9 0.650
Positive 221 87 12.8 134 12.1
Abbreviations: ER = estrogen receptor, HER2 = human epidermal growth factor receptor 





FIGURE 2. Percentage of patients with stroma-low and stroma-high tumors stratified 
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Evaluation of the prognostic value of the TSR in older patients with breast 
cancer
The FOCUS Study
Most of the 619 tumors were categorized as stroma-high (67%). Eighty-five patients 
developed a tumor recurrence. Among stroma-high tumors, a higher number of 
patients with positive lymph nodes (p = 0.004), an advanced T-stage (p = 0.014) 
and hormonal therapy (p = 0.038) was observed. Older age was associated with 
stroma-high tumors (p = 0.020) (table 1). After a follow-up period of 10 years, 
no statistically significant differences were observed in recurrence rates between 
stroma-low and stroma-high tumors, 18% versus 21% respectively (HR 1.13, 95% 
CI 0.72-1.78, p = 0.602) (figure 3). The results of the multivariate Cox regression 
analyses were in line with the results of the univariate analysis (HR 1.02, 95% CI 
0.59-1.78, p = 0.937) (table 3). After 10-year follow-up, the relative survival rates 
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of patients with stroma-low compared to stroma-high tumors were 90.2% versus 
91.6%, respectively (RER 1.53, 95% CI 0.31-7.47, p = 0.601).
The interaction term was added in the Cox regression analysis. These analyses 
showed no statistically significant value for the TSR if stratified by grade 
(p = 0.571), morphology (p = 0.449), ER status (p = 0.598), PR status (p = 0.737), 
HER2 status (p = 0.721) or tumor size (p = 0.571).
In the FOCUS study, survival analyses were performed for the TSR at other cut-off 
values than the established 50%. The cut-off values ranged from 20% to 70%, but 
none of the values showed statistically significant differences on clinical outcome 
(data not shown).
FIGURE 3. Kaplan-Meier analysis for recurrence-free period stratified by the tumor-stro-
ma ratio of patients included in the FOCUS study.
Numbers at risk
Stroma-low 204 130 13































TABLE 2. Statistically significant difference between stroma-low and stroma-high tumors 
in the Nottingham Breast Cancer series.
Stroma-low Stroma-high
n  n = 681 % n = 1113 % p-value
Age (in years)
1793 54 (mean) 55 (mean) 0.003
Grade
I 279 105 15.4 174 15.6 0.779
II 733 272 40.0 461 41.5
III 780 303 44.6 477 42.9
Histological type
Invasive carcinoma of NST 1128 450 66.1 678 61.0 0.114
Lobular carcinoma 155 53 7.8 102 9.2
Tubular carcinoma 275 90 13.2 185 16.6
Others 235 88 12.9 147 13.2
Tumor size
T1 1146 505 74.3 641 57.7 <0.001
T2 624 169 24.9 455 41.0
T3 21 6 0.9 15 1.4
Tumor involvement in lymph nodes
Negative 1127 452 66.6 675 60.8 0.013
Positive 663 227 33.4 436 39.2
ER status
Negative 331 151 22.2 180 16.2 0.002
Positive 1462 530 77.8 932 83.8
PR status
Negative 708 282 42.0 426 38.7 0.168
Positive 1066 390 58.0 676 61.3
HER2 status
Negative 1572 594 87.2 978 87.9 0.650
Positive 221 87 12.8 134 12.1
Abbreviations: ER = estrogen receptor, HER2 = human epidermal growth factor receptor 
2, NST = no special type, PR = progesterone receptor. Missing values were excluded 
from these analyses.
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DISCUSSION
The results in this study showed a significant association between age and intra-
tumoral stroma percentage expressed with the TSR; a higher amount of intra-
tumoral stroma was observed with the increase of age. This may be related to 
differences in tumor development and tumor microenvironment in older patients 
with breast cancer compared to their younger counterparts. This could be due to, 
for instance, age-related pathological alterations which occur in the mamma, such 
as an increase in fat tissue and collagenous stroma as replacement for glandular 
tissue (5, 27). The extent of the alterations in the extracellular matrix and products 
secreted by senescent fibroblasts in the promotion of late-onset breast tumorigenesis 
is still unknown. A different view on the role of senescent cells is suggested in 
recent literature. Senescent cells were previously thought to be tumor-protective, 
but recent research showed that these cells contribute to a tumor-promoting 
environment (8). A dysregulated response between declining immune function 
(i.e. immunosenescence) on one hand and a low grade chronic inflammation (i.e. 
inflammaging) on the other hand may lead to an altered tumor microenvironment. 
These processes have impact on tumor development and tumor growth in the 
aging population, probably with the involvement of CD4+ and CD8+ T cells (28). 
Previous research showed decreased values of these immune cells in mammary 
tumors in older mice compared to their younger counterparts (29). Brouwers et al. 
investigated the molecular profile of the microenvironment in older triple-negative 
breast cancer patients. The authors provided evidence that breast cancer in the 
older patients is associated with a different stromal microenvironment favorable 
for tumorigenesis, in which senescence-associated secretory profile and autophagy 
are important stromal features induced with age. As an illustration, the authors 
validated in an external publicly available dataset a significant upregulation of 
fibroblast growth factor 13 (FGF13) in tissues of older breast cancer patients. This 
gene belongs to the fibroblast growth factor superfamily. Aberrant expression of 
this superfamily is involved in tumor growth and invasion (9). Another process 
that occurs with aging are changes in the hormonal status. In postmenopausal 
women, the production of estradiol takes place in peripheral tissues instead of in 
the ovaries, like in premenopausal women. This change leads to a consistent but 




high systemic concentration of estrogen have a higher risk of developing breast 
cancer (31). The chance of random genetic errors is increased by the proliferative 
effect of estrogens on breast epithelial cells (32, 33). Whether these processes 
contribute to the increase of stroma-high patients is not known yet. Also, the 
contradictory results in this study regarding the prognostic value of the TSR is not 
fully understood. These results are in strong contrast to the discriminating power 
of the TSR regarding to clinical outcome presented in the review of Kramer and 
colleagues. The authors showed that patients with stroma-high tumors have a poor 
clinical outcome. This was observed in the overall patient population with breast 
cancer and in clinically relevant subgroups, such as, patients with triple-negative 
tumors, estrogen positive tumors or lymph node negative tumors (18). Therefore, 
the understanding and confirming of age-related changes in the microenvironment 
requires further research.
Regarding the aging patient, the tumors of older patients with breast cancer are, for 
example more often receptor positive and have a lower grade (34). In contrast to 
the more favorable biology, Van de Water et al. concluded that the clinical outcome 
in older patients with breast cancer must not be underestimated, as breast cancer 
relapse and disease specific mortality is higher in older breast cancer patients 
compared to their younger counterparts (35). A study performed in Denmark 
showed results in line with Van de Water and colleagues. The 5-year relative 
survival decreases with the increase of age; 90% for patients aged between 0-69 
years, 80% for patients aged 70-79 and 73% for women aged 80-89 years (22). Also 
the frequently used online prediction tool PREDICT slightly overestimated the 10-
year overall survival of patients aged ≥65 years and must especially be interpreted 
with caution in patients aged ≥75 years (36, 37). Dutch guidelines contain no 
explicit recommendations about chemotherapy in older patients, mainly due to the 
scarce amount of studies specifically focusing on older patients. This results in lack 
of evidence about the efficiency of chemotherapy in patients over 70 years. In daily 
clinical practice in the Netherlands, chemotherapy is advised in fit older patients 
over 70 years. Shared-decision making between oncologists and patients plays a 
role in this process. A better prediction rule for prognosis combined with research 
about the definition of ‘fit’ and the effectiveness and side effects of chemotherapy 
in older patients, might simplify decision making regarding adjuvant therapeutic 
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options. Based on the result that TSR seems to be an important prognostic marker 
in patients under the age of 70 in contrast to older patients, we advocate for the 
importance of validating other prognostic parameters in older patients.
With respect to this study, the chosen endpoint might have an effect on the outcome 
of the prognostic value of the TSR. With RFP as primary endpoint, it remains 
possible that metastases or recurrences are not filed if the observation of disease 
relapse has no clinical consequence, for example if patients are unfit for further 
treatment. To minimize the effect of competing mortality on survival, the second 
endpoint was determined as RS instead of OS. A final limitation of this study 
is that adjuvant treatment options have changed over the years. Advantages of 
the FOCUS study are the long follow-up period and the amount of patients. In 
order to give a more definitive conclusion about the prognostic value of the TSR 
in the older patient with breast cancer, it is necessary to do a large observational 
population-based cohort study of older breast cancer patients treated following 
current guidelines assembled in a detailed database with focus on recurrences and 
disease specific survival.
CONCLUSIONS
The intra-tumoral stroma increases with age. The TSR showed no correlation with 
survival in patients of 70 years or older in contrast to young women with breast 
cancer as published previously.
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The prognostic value of the tumor-
stroma ratio in tumor-positive axillary 






The tumor-stroma ratio (TSR) has previously been found to be a strong prognostic 
parameter in primary breast cancer tumors. Since the presence of tumor cells in 
lymph nodes is important for clinical decision making, the influence of the TSR in 
the primary breast tumor combined with the TSR in tumor-positive lymph nodes 
on prognosis was evaluated.
Methods
Women with invasive breast cancer without distant metastasis who underwent an 
axillary lymph node dissection between 1985 and 1994 at the Leiden University 
Medical Center were analyzed retrospectively. TSR assessment was performed on 
hematoxylin and eosin stained tissue slides.
Results
In total, 87 (45.5%) primary tumors were scored as stroma-low and 104 (54.5%) as 
stroma-high. Patients with a high stromal percentage in the primary tumors had a 
statistically significant worse relapse-free period (RFP) compared to stroma-low 
tumors (HR 1.97, 95% CI 1.37-2.82, p < 0.001). A total number of 915 lymph nodes 
were assessed for the TSR. In 101 (52.9%) patients, heterogeneity was observed 
between stroma percentage category in the primary tumor and lymph nodes. The 
combination of the TSR of the primary tumor and the TSR of tumor-positive lymph 
nodes strengthened each other as an independent prognostic parameter for RFP 
(p = 0.019). Patients with primary tumor stroma-low/lymph nodes stroma-low 
tumors showed strongly improved RFP rates compared to patients with primary 
tumor stroma-high/lymph node stroma-high tumors with 10-year percentages of 
58% versus 8%, respectively.
Conclusions
Assessing the TSR on tumor-positive lymph nodes can provide additional 
prognostic information. Stromal activation strongly differs between primary tumors 
and lymph node metastases.
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INTRODUCTION
In patients with invasive breast cancer, the presence of a regional lymph node 
(LN) metastasis is one of the most important prognostic parameters for long-term 
prognosis (1). Careful evaluation of LN status is crucial to decide whether patients 
should undergo an axillary lymph node dissection (ALND) or axillary radiotherapy 
and also plays a large role in deciding on adjuvant chemotherapy. As breast cancer 
is a heterogeneous disease (2), distinguishing patients who need more aggressive 
therapy from patients who would benefit from a more conservative approach 
remains a difficult challenge. Prognostic parameters derived from the stromal 
compartment might provide an important tool. The interaction between tumor 
cells and cells in the tumor microenvironment has gained significant interest in 
the last two decades. The tumor stroma consists of inflammatory cells, capillaries, 
fibroblasts and extracellular matrix (3). Fibroblasts that surround and infiltrate the 
primary tumor (PT), the so-called cancer-associated fibroblasts (CAFs), are believed 
to play a key role in tumor progression by secreting chemokines and growth 
factors. This may lead to increased cancer cell proliferation, promoting motility 
and invasiveness, enhanced angiogenesis and tumor-promoting inflammation (4, 5).
Based on the analysis of hematoxylin and eosin (H&E) stained histologic slides, 
our research group developed an internationally validated prognostic tool, the 
tumor-stroma ratio (TSR). This tool assesses the amount of stromal proliferation 
within the borders of the PT. This parameter has shown to be of high prognostic 
value in several types of epithelial neoplasms, including breast cancer (6-10), colon 
cancer (11-14), gastric cancer (15) and esophageal cancer (16). These studies have 
invariably shown a worse prognosis in patients with so-called stroma-high tumors 
compared to patients with stroma-low tumors.
The additional prognostic value of TSR assessment in metastatic LNs for disease-
free survival (DFS) in patients with stage III colorectal cancer was published 
by Van Pelt et al. (17). By our knowledge, the influence of stromal growth in 
LNs affected by breast cancer has not yet been investigated. The objective of this 
current study was to evaluate the prognostic value of the TSR in the primary tumor 
combined with the TSR in tumor-positive LNs in primary breast tumors compared 






The patients included in this study were selected from a database consisting of 
patients with invasive breast cancer without distant metastasis, who were primarily 
treated with surgery between 1985 and 1994 at the Leiden University Medical 
Center. Patient data were assessed retrospectively (n = 677). Only patients who 
underwent an axillary lymph node dissection were included in this study. Patients 
with a history of cancer (other than basal cell carcinoma or cervical carcinoma in 
situ), bilateral breast cancer or absence of resected tissue slides were excluded, 
leaving 193 patients for analysis. The resected tumors were graded by an 
experienced breast cancer pathologist using the current pathological standards. 
TSR assessment of the primary breast tumors was described earlier (9). All samples 
were handled in a coded fashion, according to national ethical guidelines (“Code for 
Proper Secondary Use of Human Tissue”, Dutch Federation of Medical Scientific 
Societies).
TSR assessment
The TSR was visually assessed by conventional light microscopy on 5 µm routine 
H&E stained slides. First, the PT and LNs were evaluated with a 5x objective 
to identify the most stroma-rich tissue area(s). The most stroma-abundant area 
was selected and assessed with a 10x objective. Only tumor fields with tumor 
cells present at all borders of the image field were eligible. The stroma percentage 
was scored by increments of 10%. A stroma percentage ≤50% was categorized as 
stroma-low and a stroma percentage >50% was considered stroma-high (Figure 1). 
Positive LNs were identified as stroma-high if at least one of the LNs had a stroma 
percentage of >50% (figure 1). Lymph node metastases of >0.2 mm but ≤2 mm 
were defined as micrometastases. In the case of micrometastases, the TSR was 
evaluated in a smaller image field as long as tumor cells were present at all borders.
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FIGURE 1. Examples of the tumor-stroma ratio in breast cancer. Lymph nodes were 
scanned with an automated scanning system (Philips Ultra Fast Scanner 1.6 RA) at 20x 
magnification.
a. Primary tumor stroma-low b. Primary tumor stroma-high c. Stroma-low tumor-positive 
lymph node d. Stroma-high tumor-positive lymph node.
Statistical analyses
SPSS software version 23.0 (SPSS Inc., IBM Company Chicago, IL, USA) was used 
to perform the statistical analyses. Cohen’s kappa value was used to assess the inter-
observer agreement. A value above 0.6 was considered as valid. The χ2 test was used 
for the evaluation of statistically significant differences for categorical variables 
between patients with stroma-high or stroma-low tumors. For numerical variables 




test. Statistically significant differences of non-parametric variables were analyzed 
using the Mann-Whitney U test. The primary endpoint was the relapse-free period 
(RFP), which was defined as the time from date of surgery until local, regional or 
distant recurrence of breast cancer. Patients who died or were lost to follow-up were 
censored at the last date on which they were known to be recurrence-free and/or 
alive. The definition of secondary endpoint overall survival (OS) was the time from 
date of surgery until death from any cause. Kaplan-Meier curves were compared 
with log-rank tests to assess differences in RFP. Univariate and multivariate Cox 
regression analyses were calculated for RFP and OS. Parameters with a p-value of 
less than 0.10 in univariate analysis were entered in multivariate analysis. For all 
analyses, a p-value of less than 0.05 was considered statistically significant. Effect 
modification was evaluated by adding interaction in the Cox regression analysis.
RESULTS
Patients
In total, H&E slides derived from 193 breast cancer patients could be evaluated for 
the TSR. Two patients were excluded due to poor quality of LN tissue slides, leaving 
191 patients for analysis. The study group consisted of women with a median age 
at time of diagnosis of 57.4 years (range 27.5-87.6 years). The median follow-up 
period was 7.3 years (range 0.2-23.0 years). Table 1 provides a detailed overview 
of patient characteristics.
TABLE 1. Patient characteristics and statistically significant differences between stroma-
low and stroma-high primary tumors calculated with the χ2 test.
Stroma-low Stroma-high
n n = 87 % n = 104 % p-value
Age (in years)
<40 15 9 10.3 6 5.8 0.364
>40-60 94 39 44.8 55 52.9
>60 82 39 44.8 43 41.3
Grade
I 18 5 5.7 13 12.5 0.170
II 85 37 42.5 48 46.2
III 88 45 51.7 43 41.3
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TABLE 1. Continued.
Stroma-low Stroma-high
n n = 87 % n = 104 % p-value
Histological type
Ductal carcinoma 171 83 96.5 88 85.4 0.010
Lobular carcinoma 18 3 3.5 15 14.6
Tumor stage
pT1 42 16 18.6 26 26.3 0.449
pT2 109 54 62.8 55 55.6
pT3/4 34 16 18.6 18 18.2
Nodal stage
pN1 148 75 86.2 73 70.2 0.011
pN2 11 1 1.1 10 9.6
pN3 32 11 12.6 21 20.2
ER status
Negative 83 40 47.1 43 44.8 0.760
Positive 98 45 52.9 53 55.2
PR status
Negative 86 36 42.4 50 51.0 0.241
Positive 97 49 57.6 48 49.0
HER2 status
Negative 118 57 82.6 61 82.4 0.978
Positive 25 12 17.4 13 17.6
Surgery with or without radiotherapy
MST without RT 62 30 34.5 32 30.8 0.860
MST with RT 63 28 32.2 35 33.7
BCS without RT 0 0 0 0 0
BCS with RT 76 29 33.3 37 35.6
Chemotherapy
No 127 52 59.8 75 72.1 0.072
Yes 64 35 40.2 29 27.9
Hormonal therapy
No 136 61 70.1 75 72.1 0.761
Yes 55 26 29.9 29 27.9
Abbreviations: BCS = breast conserving therapy, ER = estrogen receptor, HER2 = human 





Prognostic value of the TSR in the primary tumor
In total, 87 (45.5%) PTs were determined to be stroma-low and 104 (54.5%) as 
stroma-high. Patients with stroma-high PTs had a statistically significant worse 
RFP compared to stroma-low tumors (HR 1.97, 95% CI 1.37-2.82, p < 0.001) (figure 
2). After 10 years of follow-up, 75% of patients with stroma-high tumors developed 
a recurrence compared to 46% of patients with stroma-low tumors. The multivariate 
analysis showed that the TSR in the PT is a statistically significant independent 
prognostic factor for RFP (HR 1.70, 95% CI 1.16-2.49, p = 0.006) (table 2) and OS 
(HR 1.49, 95% CI 1.04-2.14, p = 0.029) (supplementary table 1). In the stroma-
high group, statistically significant more patients had a tumor of lobular type and 
a higher nodal stage (table 1). The TSR assessment of the PTs in the total group of 
patients was previously published by our group (9). The tissue slides were scored 
in a blinded fashion by a second observer with a Cohen’s kappa of 0.85 (almost 
perfect agreement).
FIGURE 2. Kaplan-Meier analysis for relapse-free period of patients with stroma-low 






















86 49 35 14
Primary tumor stroma-
high
102 32 22 11
p < 0.001
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The TSR in tumor-positive lymph nodes
In total, 915 LNs were analyzed (range 1-18 per patient). LNs were categorized as 
stroma-high if at least one of the LNs had a stroma percentage of >50%. The LNs 
of 160 (83.8%) patients were scored as stroma-low and 31 as stroma-high (16.2%). 
Stroma-low PTs and stroma-low LNs were seen in 73 patients (38.2%). Stroma-high 
PTs and stroma-high LNs were seen in 17 patients (8.9%). In 101 (52.9%) patients, 
heterogeneity was observed between the stroma percentage category in the primary 
tumor and in the lymph nodes. No interaction between the TSR in the PTs and 
LNs was found, as well as between the TSR in LNs and nodal status. The Mann-
Whitney U test did not show a statistically significant difference between lymph 
node yield (not normally distributed) and the TSR category of LNs. In 10 patients, 
only micrometastases were observed. These small tumor fields consisted of tumor 
cells for more than 90%. Thirty percent of the LNs were scored in a blinded fashion 
by a second observer with a Cohen’s kappa of 0.79.
Prognostic value of the TSR in primary tumor combined with tumor-posi-
tive lymph nodes
The TSRs of the PT and positive LNs were combined to evaluate the possibility 
of an additional prognostic effect. The four different combinations of the TSR (PT 
stroma-low/LNs stroma-low, PT stroma-low/LNs stroma-high, PT stroma-high/
LNs stroma-low and PT stroma-high/LNs stroma-high) were plotted for the RFP 
with an overall p-value of 0.001 (figure 3). The patient characteristics of these four 
groups were described in supplementary table 2. Patients with PT stroma-low/LNs 
stroma-low showed better 10-year RFP rates compared to patients with PT stroma-
high/LNs stroma-high with percentages of 58% versus 8%, respectively. These 
analyses showed a strong prognostic impact of high amounts of stroma in the PT as 
well as LNs with regard to RFP. Multivariate analysis showed that the combination 
of the TSR in PT and LNs is an independent prognostic factor for RFP (p = 0.019) 
(table 2). A non-statistically significant trend was seen in favor of stroma-low PT/









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































FIGURE 3. Kaplan-Meier analysis for relapse-free period of patients with PT stroma-low/





























Time since date of surgery in yearsNumbers at risk
PT stroma-low/LNs 
stroma-low
73 44 33 14
PT stroma-low/LNs
stroma-high
13 5 3 1
PT stroma- high/LNs 
stroma-low
89 30 21 11
PT stroma-high/LNs 
stroma-high
17 2 1 1
0,2
Abbreviations: LN = lymph node, PT = primary tumor
DISCUSSION
This is the first study investigating the TSR in tumor-positive LNs in patients with 
invasive breast cancer. Patients with LN metastases were previously considered 
to be immediately eligible for adjuvant chemotherapy, irrespective of other clinic-
pathological parameters. As studies have shown that patients with 1-3 positive 
LNs do not necessarily have a worse prognosis compared to node-negative tumors, 
subsequent guidelines have since stated that LN involvement in itself is not a reason 
for adjuvant chemotherapy (18). However, further research is needed to refine the 
109
THE TUMOR-STROMA RATIO AND TUMOR-POSITIVE LYMPH NODES
prognosis of lymph node-positive patients further, both to omit chemotherapy in 
some cases or possibly to escalate chemotherapy for others.
Analogous to our work regarding the prognostic implication of stromal proliferation 
in PTs, we investigated the added significance of assessing stroma in breast cancer 
positive LNs. We found that incorporating the TSR of LNs combined with the 
TSR of the corresponding PT provided a superior prediction of RFP compared to 
the TSR of the PT alone. When the TSR is solely evaluated in the PT, the disease 
recurrence rate after 10 years is 75% in primary stroma-high tumors, whereas the 
number is 46% in primary stroma-low tumors. When the TSR of the LNs is added 
to these two groups, a group of patients with high risk can be identified, namely PT 
stroma-high/LNs stroma-high. Considering that this patient group has a recurrence 
rate of 92% after 10 years, this method seems capable of identifying a group of 
patients with a worse prognosis.
An interesting result is a strong discrepancy between the TSR in the PT and the 
LNs of the same patients. In 101 (52.9%) patients, heterogeneity was observed 
between the stroma percentage category in the PT and LNs. Only a small proportion 
of patients was scored as stroma-high when evaluating the LNs (n = 31), which 
is in stark contrast with the fairly large amount of stroma-high PTs (n = 104). 
Consequently, a high number of patients with stroma-high tumors presented with 
stroma-low LN metastases. This finding might be reflective of differential activity 
of signaling processes across primary and metastatic tumors. The formation of 
genetically and transcriptionally distinct subclones of tumor cells that arise during 
tumor evolution might influence the activation of tumor-associated stroma as well 
as tumor cell dissemination. In the current study, we found that at least one LN with 
a high amount of stroma was predictive for a statistically significant decreased RFP.
A previously published study by Van Pelt et al. also showed the additional value 
of the TSR in lymph nodes. The authors concluded that the assessment of the 
TSR in the PT combined with the TSR in metastatic LNs has an additional value 
with regards to the prediction of DFS in patients treated with adjuvant therapy for 
stage III colon cancer (17). Incorporating the TSR in clinical practice has certain 
advantages compared to other potential biomarkers. TSR scoring can be carried 
out on standard H&E slides and is performed by visually eyeballing the tissue 




minute and requires no additional costs. Implementation of this method in daily 
practice is, therefore, an easy and non-expensive option. The concordance of the 
inter-observer variability has been high between researchers from our group, which 
is also confirmed in the current study (6, 10, 14).
The patients for this study were primarily treated with surgery between 1985 and 
1994 and are part of a well-characterized treatment cohort with long-term follow-
up. However, this obviously means that modern-day adjuvant chemotherapy and 
hormonal regimens and selection of these treatment modalities according to current 
guidelines were not applied to this dataset. This is reflected by the relatively poor 
prognosis of the included patients compared to currently treated patient groups. 
Therefore, before definitive conclusions can be drawn regarding the prognostic and 
therapeutic implication of tumoral LN fibrosis, validation of the current results in 
modern-day cohorts should be undertaken.
Lastly, according to treatment guidelines, breast cancer patients first undergo a 
sentinel lymph node biopsy (SLNB) in case of no suspicion of positive lymph 
nodes by ultrasound or clinical examination (1). Depending on the presence of LN 
metastasis, an ALND will be performed. Evaluation of the TSR in a tumor-positive 
LN dissected during sentinel node procedure is interesting. A recent publication 
from Giuliano et al. showed that a less invasive SLNB alone was non-inferior to 
predicting overall survival compared to ALND in women with T1 or T2 tumors, no 
palpable axillary lymphadenopathy and 1 or 2 positive sentinel LNs (19). Evaluation 
of the TSR in sentinel nodes could be an important next step to evaluate if this 
clinical prognostic marker can select patients who will benefit from ALND or 
axillary radiotherapy.
CONCLUSIONS
The TSR is a simple, fast and cheap method. Assessing the TSR on tumor-positive 
LNs can provide further prognostic stratification in breast cancer patients. Stromal 
activation strongly differs between PTs and LN metastases, likely reflecting 
heterogeneity of the tumor stroma metastatic process.
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SUPPLEMENTARY TABLE 1. Univariate and multivariate analyses for overall survival 
calculated by Cox regression analysis.
Overall Survival
Univariate analysis Multivariate analysis: 
TSR in PT
Multivariate analysis: 
TSR PT and LNs
n HR 95% CI p-value HR 95% CI p-value HR 95% CI p-value
Age (in years)
<40 15 <0.001 0.296 0.305
>40-60 94 1.25 0.62-2.51 0.70 0.33-1.48 0.73 0.34-1.55
>60 82 2.40 1.20-4.80 0.91 0.41-2.02 0.95 0.42-2.15
Grade
I 18 0.835
II 85 1.06 0.59-1.88










pT2 109 1.17 0.78-1.77
pT3/4 34 1.44 0.86- 2.42
Nodal stage
pN1 148 <0.001 0.269 0.280
pN2 11 2.74 1.46-5.16 1.69 0.88-3.27 1.67 0.86-3.22
pN3 32 1.94 1.29-2.92 1.20 0.75-1.91 1.21 0.76-1.93
ER status
Negative 83 0.809
Positive 98 1.04 0.75-1.46
PR status
Negative 86 0.006 0.504 0.523
Positive 97 0.63 0.45-0.88 0.89 0.62-1.26 0.89 0.62-1.27
HER2 status
Negative 118 0.736
Positive 25 0.92 0.55-1.52
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SUPPLEMENTARY TABLE 1. Continued.
Overall Survival
Univariate analysis Multivariate analysis: 
TSR in PT
Multivariate analysis: 
TSR PT and LNs
n HR 95% CI p-value HR 95% CI p-value HR 95% CI p-value
Surgery with or without radiotherapy
MST without 
RT
62 0.001 0.021 0.033




BCS with RT 66 0.51 0.34-0.77 0.58 0.37-0.91 0.60 0.38-0.94
Chemotherapy
No 127 <0.001 <0.001 <0.001
Yes 64 0.35 0.23-0.52 0.41 0.26-0.66 0.42 0.26-0.68
Hormonal therapy
No 136 0.126
Yes 55 1.31 0.93-1.86
TSR
Stroma-low 87 0.003 0.029
Stroma-high 104 1.65 1.86-2.29 1.49 1.04-2.14






14 2.14 1.11-4.14 0.023 1.56 0.78-3.14 0.209
PT high/LN 
low
87 1.73 1.20-2.49 0.003 1.55 1.05-2.29 0.029
PT high/LN 
high
17 2.50 1.41-4.42 0.002 1.91 1.03-3.52 0.039
Abbreviations: BCS = breast conserving therapy, ER = estrogen receptor, HER2 = human 
epidermal growth factor receptor 2, LN = lymph nodes, MST = mastectomy, PR = progesterone 




SUPPLEMENTARY TABLE 2. Patient characteristics categorized in patients with 
stroma-low PTs/stroma-low LNs, stroma-low PTs/stroma-high LNs, stroma-high PTs/













n = 73 % n = 14 % n = 87 % n = 17 % p-value
Age (in years)
<40 8 11.0 1 7.1 4 4.6 2 11.8 0.281
>40-60 35 47.9 4 28.6 49 56.3 6 35.3
>60 30 41.1 9 64.3 34 39.1 9 52.9
Grade
I 5 6.8 0 0 10 11.5 3 17.6 0.475
II 32 43.8 5 35.7 41 47.1 7 41.2
III 36 49.3 9 64.3 36 41.4 7 41.2
Histological type
Ductal carcinoma 69 95.8 14 100 72 83.7 16 94.1 0.034
Lobular carcinoma 3 4.2 0 0 14 16.3 1 5.9
Tumor stage
pT1 15 20.8 1 7.1 22 26.8 4 23.5 0.248
pT2 46 63.9 8 57.1 43 52.4 12 70.6
pT3/4 11 15.3 5 35.7 17 20.7 1 5.9
Nodal stage
pN1 63 86.3 12 85.7 62 71.3 11 64.7 0.095
pN2 0 0 1 7.1 8 9.2 2 11.8
pN3 10 13.7 1 7.1 17 19.5 4 23.5
ER status
Negative 33 45.8 7 53.8 36 45.0 7 43.8 0.943
Positive 39 54.2 6 46.2 44 55.0 9 56.3
PR status
Negative 28 38.9 8 61.5 41 50.0 9 56.3 0.278
Positive 44 61.1 5 38.5 41 50.0 7 43.8
HER2 status
Negative 49 83.1 8 80.0 52 83.9 9 75.0 0.895
Positive 10 16.9 2 20.0 10 16.1 3 25.0
Surgery with or without radiotherapy
MST without RT 23 31.5 7 50.0 29 33.3 3 17.6 0.268
MST with RT 22 30.1 6 42.9 27 31.0 8 47.1
BCS without RT 0 0 0 0 0 0 0 0
BCS with RT 28 38.4 7.1 31 35.6 6 35.3
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n = 73 % n = 14 % n = 87 % n = 17 % p-value
Chemotherapy
No 42 57.5 10 71.4 63 72.4 12 7.06 0.233
Yes 31 42.5 4 28.6 24 27.6 5 29.4
Hormonal therapy
No 53 72.6 8 57.1 63 72.4 12 70.6 0.686
Yes 20 27.4 6 42.9 24 27.6 5 29.4
Abbreviations: BCS = breast conserving therapy, ER = estrogen receptor, HER2 = human 
epidermal growth factor receptor 2, LNs = lymph nodes, MST = mastectomy, 
PR = progesterone receptor, PT = primary tumor, RT = radiotherapy
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Prognostic value of the tumor-stroma 
ratio combined with the immune status 






The tumor microenvironment coexists of complex interactions between cancer 
cells and cells in the microenvironment. In this study, the prognostic value of the 
interplay between the tumor-stroma ratio (TSR) and the immune status of tumors 
in breast cancer patients was evaluated.
Methods
A cohort of 574 breast cancer patients was analyzed. The percentage of tumor 
stroma was visually estimated on hematoxylin and eosin (H&E) stained histological 
tumor tissue sections. Immunohistochemical staining was performed for classical 
human leukocyte antigen (HLA) class I, HLA-E, HLA-G, markers for regulatory 
T (Treg) cells, natural killer (NK) cells and cytotoxic T lymphocytes (CTLs).
Results
The TSR (p < 0.001) and the immune status of tumors (p < 0.001) were both 
statistically significant for the recurrence-free period (RFP) and both independent 
prognosticators (p < 0.001) in which tumors with a high stromal content behave 
more aggressively as well as tumors with a low immune status. The 10-year 
RFP for patients with a stroma-low tumor and high immune status profile was 
87% compared to 17% of patients with a stroma-high tumor combined with a 
low immune status profile (p < 0.001). The classical HLA class I was the most 
prominent immune marker in the immune status profiles.
Conclusions
Determination of the TSR is a simple, fast and cheap method. The effect on RFP 
of the TSR when combined with the immune status of tumors or expression of 
classical HLA class I is even stronger. Both are promising for further prediction 
and achievement of tailored treatment for breast cancer patients.
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INTRODUCTION
Survival for patients with invasive breast cancer has increased in the last decade 
due to new and improved therapeutic options as well as new insights in molecular 
biology. Methods to select patients based on tumor phenotype are important to 
reduce over- and undertreatment. For example, gene expression profiles that identify 
subtypes (1, 2) associated with higher risk of metastasis. Although these techniques 
result in prognostic and predictive valuable information for specific patient groups, 
optimization of risk assessment might benefit from further improvement.
Despite an important update on the role of the microenvironment on cancer 
development by Hanahan et al. (3, 4), the classification system for predicting 
metastasis and disease-specific survival is still based on traditional tumor staging 
criteria (AJCC/UICC-TNM Classification) (5-7), which focusses largely on the 
tumor cell-autonomous processes and not on the microenvironment.
The tumor microenvironment coexists of complex interactions between cancer cells 
and cells in the microenvironment, such as immune and stromal cells. High stromal 
content is associated with worse prognosis in different solid cancer types, including 
breast cancer and especially triple-negative breast cancer (8-14). Together with the 
development of malignant tumor stroma, the connective tissue framework of the 
tumor becomes active. The collagen bundles degrade, the number of inflammatory 
cells increases, fibroblasts differentiate into myofibroblasts and proliferate, and 
angiogenesis increases (15). Also, the cellular immune response has a fundamental 
role in cancer development. An example of the prognostic value of the activity 
of the immune system is represented by the Immunoscore, which analyzes the 
distribution of CD3+ lymphocytes and CD8
+ cytotoxic T cells (16). In breast cancer, 
especially in triple-negative tumors, the increased presence of tumor- infiltrating 
lymphocytes has been associated with good prognosis (17, 18). De Kruijf et al. 
showed that the immune status of tumors, which is based on six cellular immune 
markers, has a statistically significant effect on prognosis in favor of tumors with 
a high immune status (19). These six cellular immune markers (HLA-E, HLA-G, 
classical HLA class I (HLA-A, HLA-B and HLA-C), natural killer (NK) cells, 
cytotoxic T lymphocytes (CTLs) and regulatory T (Treg) cells) were selected based 




It is suggested that the tumor stroma influences the suppression of the immune 
response (9, 20-23). In this present study, the prognostic value of the interplay 
between the tumor-stroma ratio (TSR) and the immune status of tumors in breast 
cancer patients was evaluated. We hypothesize that stroma-high tumors, in 
combination with low immune status, behave more aggressively, resulting in a 
high risk of disease progression.
MATERIALS AND METHODS
Study population
The study population was assessed retrospectively and consisted of primary non-
metastasized breast cancer patients. The patients were primarily treated with 
surgery between 1985 and 1994 at Leiden University Medical Center (n = 584). 
Exclusion criteria were bilateral breast tumors and a history of cancer (other than 
basal cell carcinoma or cervical carcinoma in situ). The resected breast tumors 
were graded by experienced breast cancer pathologists using current pathological 
standards. All samples were handled in a coded fashion, according to the national 
ethical guidelines (“Code for Proper Secondary Use of Human Tissue”, Dutch 
Federation of Medical Scientific Societies). Approval of the study was obtained 
from the LUMC Medical Ethics Committee. The recommendations for reporting on 
tumor markers (the REMARK criteria) in prognostic studies were respected (24).
Tumor-stroma ratio
The TSR was visually estimated on routine hematoxylin and eosin (H&E) stained 
slides from formalin-fixed and paraffin-embedded (FFPE) blocks of the primary 
tumor (n = 584) as previously described by our group (25). Thirty-two percent of the 
tissues were scored in a blinded fashion by a second observer, with a concordance 
of classification of 94% (Cohen’s kappa = 0.85). Ten tissues were not eligible for 
TSR scoring due to poor quality. Evaluation of TSR started with microscopical 
orientation using a 5x objective. Subsequently, a 10x objective was used in the 
most stroma-abundant area. The field of highest stromal percentage was selected 
and scored per tenfold increments. Tumor cells must be present on all sides (north, 
123
THE TUMOR-STROMA RATIO AND THE IMMUNE STATUS OF TUMORS
east, south and west). Stroma percentage ≤50% was categorized as stroma-low and 
stroma percentage >50% as stroma-high (supplementary figure 1) (8, 12).
Immunohistochemistry
Tissue sections from intra-operatively derived FFPE tissue micro-array (TMA) 
material and immunohistochemistry analysis were used as previously described 
(19, 26, 27). Whole FFPE sections were immunohistochemically stained with mouse 
antibodies against CD8+ and PEN5 recognizing CTLs and NK cells, respectively. 
TMA tissue sections were immunohistochemical stained for the expression of 
classical HLA class I (anti-HLA-A and anti-HLAB/C), non-classical HLA-E, 
HLA-G and Treg cell infiltration as previously described in the literature (26, 27).
Quantification of CD8+ cells and PEN5 cells was performed in a blinded set-up by 
two independent observers. Tumor infiltration of CD8+ was divided into low CTL 
infiltration (0-100 CD8+ tumor-infiltrating cells/mm2) and high CTL infiltration 
(100-3.000 CD8+ tumor-infiltrating cells/mm2). Tumor infiltration of NK cells 
was divided into the presence or absence of NK cells. Classical HLA class I was 
categorized into loss versus expression and HLA-E was divided into no expression 
versus expression. HLA-G and Treg infiltration were categorized in absent versus 
present (supplementary figure 2).
These six immune markers were classified into three immune status profile groups 




FIGURE 1. Evaluation of the immune status and classification.
Abbreviations: CTL = cytotoxic T lymphocytes, HLA = human leukocyte antigen, 
Treg = regulatory T cells, NK = natural killer
Statistical analyses
Statistical analyses were performed using IBM SPSS statistics (version 23.0 for 
Windows). The inter-observer agreement for the assessment of TSR, CTLs and 
PEN5 was calculated with Cohen’s kappa. A value above 0.6 was valid. The χ2 
test was used for the evaluation of statistically significant differences between 
included and excluded patients, distribution of the separate immune markers 
between stroma-high and stroma-low cases and three immune status categories. 
A p-value <0.05 was considered statistically significant. The Kaplan-Meier method 
was performed to analyze the overall survival (OS) and recurrence-free period 
(RFP). The log-rank test was applied for comparison between these curves. A 
p-value <0.05 was considered statistically significant. The time from date of surgery 
until any recurrence of breast cancer was defined as RFP. The OS was defined as the 
time from date of surgery until death from any cause. Univariate and multivariate 
analyses for RFP and OS were calculated by Cox regression analysis. Variables 
with p-value <0.10 in the univariate analysis were entered in multivariate analysis. 
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Effect modification was evaluated by adding interaction in Cox regression analysis. 
Stepwise regression analyses (backward and forward) of the different immune cells 
were evaluated. Missing values were not included.
RESULTS
Patients
The FFPE blocks of all patients (n = 584) were available. TSR could be evaluated 
in 98% of the cases (n = 574). In 43% of the cases, no classification of the immune 
status could be made due to the low quality of tissues or TMAs. The loss or damage 
of TMA cores is a known problem associated with the preparation, staining and 
mounting of TMA slides.
Moreover, the cores we used were rather small. Since several markers were 
combined in the profiles, the patient was excluded from further analysis when 
data of one or more markers were missing. Figure 2 provides a flowchart of the 
subjects included. By comparison of prognostic parameters, no differences were 
found between included (n = 344) and excluded cases (n = 230), except for the 
treatment with hormonal therapy (p < 0.001). This can be explained by the fact that 
this therapy was only given sporadically between 1985 and 1988. No statistically 
significant differences were found for age, grade, tumor stage, tumor type, nodal 
stage, histological type, estrogen receptor, progesterone receptor, HER2 expression, 
TSR, chemotherapy and radiotherapy in these two groups.
The median follow-up of the 344 included patients was 10.2 years (0.2–22.4 
years). The mean age at presentation was 58.0 years (27.5–90.2 years). There is no 
statistically significant difference in the distribution of the separate markers between 
stroma-high and stroma-low cases, nor in the three immune status categories 
(p = 0.30). Table 1 provides a detailed overview of the immune markers stratified 




FIGURE 2. Flowchart of subject inclusion.
Patients with non-metastatic invasive breast cancer 
primarily treated with surgery between 1985 and 1994 
n = 584
No FFPE blocks were available
n = 0
HLA class I expression could not be 
assessed   n =  51
Total number of patients used in analysis
n = 344
HLA-E expression could not be 
assessed  n = 82 
HLA-G expression could not be 
assessed   n = 73
The TSR category could not be 
assessed 
n = 10
NK cell infiltration could not be 
assessed   n = 44
CTL infiltration could not be 
assessed   n = 79
Treg cell infiltration could not be 
assessed   n = 18
No immune susceptibility classification could be assessed
n = 230*
* For categorizing in one of the three immune status categories, not all six groups need to 
be known.
Abbreviations: CTL = cytotoxic T lymphocyte, FFPE = formalin-fixed and paraffin-
embedded, NK = natural killer, Treg = regulatory T, TSR = tumor-stroma ratio.
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TABLE 1. Distribution of the separate elements of the three immune status profiles.
Stroma-low Stroma-high
n = 177 % n = 167 % p-value
HLA class I
Loss or downregulation 98 55.4 103 61.7 0.24
Expression 79 44.6 64 38.3
HLA-E
Negative 97 54.8 93 55.7 0.87
Positive 80 45.2 74 44.3
HLA-G
Negative 108 61.0 105 62.9 0.72
Positive 69 39.0 62 37.1
NK cells
Negative 78 44.1 79 47.3 0.47
Positive 95 53.7 82 49.1
Missing 4 2.2 6 3.6
CTL
Low infiltration 115 65.0 121 72.5 0.19
High infiltration 55 31.0 42 25.1
Missing 7 4.0 4 2.4
Treg cells
Absence 97 54.8 98 58.7 0.62
Presence 74 41.8 67 40.1
Missing 6 3.4 2 1.2
Immune status profiles
High IS 39 22.0 26 15.5 0.30
Intermediate IS 108 61.0 109 65.3
Low IS 30 17.0 32 19.2
The subtypes were constructed according to the criteria shown in table 1. Only the 
cases for which both stromal content and immune subtyping could be performed, were 
included in the analysis.
Abbreviations: CTL = cytotoxic T lymphocyte, HLA = human leukocyte antigen, 




TABLE 2. Patient characteristics.











Ductal carcinoma 309 89.8
























Luminal A 192 55.8
Luminal B 10 2.9
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TABLE 2. Continued.





MST without RT 143 41.6
MST with RT 64 18.6
BCS without RT 1 0.3














Combination TSR and immune status
Stroma-low/high IS 39 11.3
Stroma-low/intermediate IS 108 31.4
Stroma-low/low IS 30 8.7
Stroma-high/high IS 26 7.6
Stroma-high/intermediate IS 109 31.7
Stroma-high/low IS 32 9.3
Abbreviations: BCS = breast conserving therapy, 
ER = estrogen receptor, HER2 = human epidermal 
growth factor receptor 2, IS = immune status, 
MST = mastectomy, PR = progesterone receptor, 




Prognostic value of the TSR
Tumors with low and high stromal contents were observed in 51.5% and 48.5% 
of the cases (n = 574), respectively. Patients with stroma-high tumors had a worse 
RFP (HR 1.75, 95% CI 1.37-2.25, p < 0.001) and OS (HR 1.28, 95% CI 1.04-1.58, 
p = 0.02) compared to patients with stroma-low tumors (not shown). After 10 
years, 32% of the patients with a stroma-low tumor had developed a recurrence of 
disease compared to 50% of patients with a stroma-high tumor. These results for 
RFP in favor of stroma-low tumors were also seen in the group of patients (n = 344) 
in which the immune status could be assessed (HR 1.76, 95% CI 1.28- 2.42, p < 
0.001) (figure 3a) with a 10-year RFP of 67% for patients in the stroma-low group 
compared to 49% in the stroma-high group. OS showed no significant difference 
between both stroma groups (HR 1.25, 95% CI 0.95-1.64, p = 0.114). The analyses 
of breast cancer subgroups showed that patients with a triple-negative tumor had 
a high hazard ratio of 2.41 (95% CI 1.32-4.40, p = 0.003) for RFP in both the total 
group (known TSR), as well as in the selected group (known TSR and immune 
status). Furthermore, within the luminal A subgroup, the TSR showed a significant 
difference in RFP (HR 1.57, 95% CI 1.13-2.19, p = 0.008), but not for OS. For the 
other subgroups (Luminal B and HER2-like tumors) no prognostic value of the 
TSR was found (supplementary table 1a and 1b).
Prognostic value of the immune status of tumors
The immune status of tumors was classified as high in 18.9%, intermediate in 63.1% 
and low in 18.0% of the breast cancer cases. The RFP (figure 3b) and OS curves 
(not shown) of the three immune status categories were statistically significant (p 
< 0.001) in which patients with a high immune status profile had a better outcome 
compared to patients with a low immune status profile. After 10 years of follow-up, 
79% of the patients in the high immune status category did not develop a recurrence 
of disease compared to 58% in the intermediate immune status category and 36% 
in low immune status category. The analyses of breast cancer subgroups showed 
that patients with a luminal A or triple-negative tumor have a worse prognosis for 
both RFP and OS (supplementary table 2).
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Prognostic value of the TSR and the immune status of tumors combined
The RFP data of the TSR and the immune status subtypes were combined and 
plotted in figure 3c. The overall p-value between the subgroups was statistically 
significant (p < 0.001) (table 3). A trend was observed for stroma-high tumors 
compared to stroma-low tumors with a high immune status profile (p = 0.15) and 
intermediate immune status profile (p = 0.08). However, only for the low immune 
status profile, the difference between stroma-high and stroma-low tumors showed 
significance (p = 0.002). The 10-year RFP for stroma-low and high immune status 
showed a recurrence rate of 87% versus 17% of patients with stroma-high and low 
immune status tumors.
Table 3 shows the results of the univariate and multivariate Cox regression analyses. 
The TSR remained statistically significant for RFP (p < 0.001) in multivariate Cox 
regression analysis and the immune status for RFP (p < 0.001) and OS (p = 0.001). 
Effect modification of stroma and immune status was not statistically significant. 
As expected, the TSR combined with immune status showed additional prognostic 
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Prognostic value of the TSR combined with classical HLA class I
A stepwise regression analysis was performed to evaluate whether one or more of 
the six cellular immune cells were decisive in the immune status categories. In this 
analysis classical HLA class I showed to be statistically significant in the immune 
status categories for RFP (p = 0.007), but not for OS (p = 0.06), whereas the other 
immune cells were not significant for both RFP and OS. These results indicate that 
classical HLA class I is the most determinant factor in the three immune status 
profiles. In 523 of the 574 cases (91%) classical HLA class I could be assessed. 
Tumors expressing classical HLA class I had significantly fewer recurrences 
(p = 0.001), with a 10-year RFP of 66% versus 55%. In the same group, the TSR 
showed RFP of 67% versus 49% in benefit for stroma-low tumors (p < 0.001).
Figure 3d shows a statistically significant difference (p < 0.001) for RFP for the 
combination of the TSR and classical HLA class I. This indicates that patients 
with a stroma-low tumor and expression of classical HLA class I have a better 
prognosis compared to patients with a stroma-high tumor and loss of expression 
or downregulation of classical HLA class I with a 10-year RFP 72% versus 46%, 
respectively.
In triple-negative tumors classical HLA class I (n = 92) was also of prognostic 
value (HR 0.28, 95% CI 0.15-0.55, p < 0.001). Patients with loss of expression or 
downregulation of classical HLA class I showed a 10-year RFP of 35% compared to 
73% of the patients in which HLA class I is expressed. The TSR and classical HLA 
class I combined showed a statistically significant difference in RFP (p = 0.001). 
Patients with stroma-low tumors and expression of classical HLA class I showed 
fewer recurrences compared to patients with stroma-high tumors and loss of 




















































































































































































































































































































































































































































There is a growing body of evidence that the TSR and immune cell response in 
cancer development might be important factors in patient stratification for treatment 
decision making. The relation of the stromal involvement and immune response for 
the determination of patients for adjuvant treatment has merely been investigated. 
Gujam et al. described the relationship between the TSR and clinicopathological 
parameters as tumor inflammatory infiltrate, CD68+ macrophage infiltrate and 
CD4+ and CD8+ T- lymphocyte infiltrate in ductal breast cancer. They concluded 
that a high TSR was consistently associated with low tumor inflammatory infiltrate 
(9). Hynes et al. also published on the combination of the TSR with peritumoral 
diffuse lymphoid inflammation and Crohn’s disease-like reaction in stage II/
III colon cancer. A combination of these three parameters showed a significant 
association with survival outcomes (23).
Our study showed that the TSR and the combination of six cellular immune cells, 
categorized into three immune status subgroups, are both independent prognostic 
factors. A combination of both parameters even strengthens each other’s’ effect.
The six cellular immune cells were selected based on biological rationale and 
the balance between their various interactions. Classical HLA class I presents 
tumor-associated antigens on the cell surface. CTLs are capable of recognizing 
the presence of these antigens by HLA-A, HLA-B or HLA-C (28). Tumor cells 
can escape recognition by CTLs by losing classical HLA class I expression. This 
makes the tumor cells more prone to recognition by NK cells (29). On the other 
hand, HLA-E and HLA-G, also known as non-classical HLA class I, play a crucial 
role in the immune surveillance by NK cells. Expression of non-classical HLA 
I has an inhibitory effect on the function of NK cells (29-31). Other cells which 
are important in tumor development are Tregs. Tumor cells can escape immune-
surveillance by attraction and induction of Tregs (32).
In this study, the prognostic value of the TSR in addition to classical HLA class 
I was also shown. The effect was smaller than the combination with the three 
immune status subgroups, but better applicable in daily routine pathology practice. 
Patients with stroma-low tumors also expressing classical HLA class I have a 
better prognosis than patients with stroma-high tumors with loss of expression or 
downregulation of classical HLA class I.
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The estimation of the TSR is simple, inexpensive and takes only a few minutes. It 
can be done on regular H&E slides during routine pathology investigation of the 
resected tissue. Since the introduction of pre-operative chemotherapy, it might 
be of interest to score the TSR on tumor biopsies. Pre-operative chemotherapy 
can lead to the formation of non-desmoplastic stroma, which makes the resection 
material unsuitable for TSR scoring. In esophageal adenocarcinoma biopsies, the 
reproducibility of TSR scoring on biopsies was good (33), and it is plausible that this 
is even better in breast cancer due to the lack of the muscular area (34). Promising 
is the current interest in the automation of the TSR parameter (13). Assessment 
of the six cellular immune markers is relatively time-consuming, however the 
assessment of only classical HLA class I takes less effort and may help to optimize 
risk stratification in combination with the TSR.
Patients with early-stage breast cancer are often treated with adjuvant systemic 
therapy (endocrine therapy, chemotherapy or agents against HER2) based on 
tumor characteristics such as HER2 status, tumor size and lymph node status. A 
substantial number of women with breast cancer is overtreated. These patients do 
not benefit from adjuvant therapy, but they are exposed to the risk of toxic effects. 
The TSR, the immune status or a combination of these prognostic markers might 
be used to select patients with more confidence regarding adjuvant treatment or 
to select patients who need more intensive monitoring. Especially patients with 
stroma-high tumors and low immune status could benefit from more aggressive 
treatment, whereas for patients with stroma-low tumors and high immune status, 
less aggressive treatment could be discussed. The method described in this paper 
could give valuable additional pathology-based information for patients with 
invasive breast cancer.
CONCLUSIONS
Simple H&E stained sections contain more information than previously fathomed. 
The TSR is a simple, fast and cheap method for the identification of patients with 
more aggressive disease. Tumor immune status profiling is promising for further 




patients. The combination of the TSR and the immune status of tumors is a strong 
prognosticator, applicable for daily routine use.
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SUPPLEMENTARY FIGURE 1. The tumor-stroma ratio. 
a. Stroma-low tumor b. Stroma-high tumor.
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SUPPLEMENTARY FIGURE 2. Continued.
Abbreviation: HLA = human leukocyte antigen
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SUPPLEMENTARY TABLE 1a. Prognostic value of the tumor-stroma ratio stratified 
for breast cancer subtypes in total group (n = 420).
Recurrence-free period Overall survival
n HR 95% CI p-value HR 95% CI p-value
Luminal A
Stroma-low 164 0.008 0.139
Stroma-high 144 1.57 1.13-2.19 1.24 0.93-1.65
Luminal B
Stroma-low 10 0.394 0.242
Stroma-high 5 1.78 0.47-6.71 2.05 0.62-6.82
HER2-like
Stroma-low 14 0.396 0.183
Stroma-high 21 1.57 0.55-4.46 1.77 0.77-4.09
Triple-negative
Stroma-low 36 0.004 0.231
Stroma-high 26 2.41 1.32-4.40 1.46 0.78-2.73
Abbreviations: HER2 = human epidermal growth factor receptor 2
SUPPLEMENTARY TABLE 1b. Prognostic value of the tumor-stroma ratio stratified 
for breast cancer subtypes within the known immune status group (n = 279).
Recurrence-free period Overall survival
n HR 95% CI p-value HR 95% CI p-value
Luminal A
Stroma-low 99 0.100 0.508
Stroma-high 93 1.42 0.94-2.15 1.13 0.79-1.62
Luminal B
Stroma-low 6 0.133 0.111
Stroma-high 4 5.69 0.59-55.19 4.07 0.73-22.88
HER2-like
Stroma-low 5 0.953 0.891
Stroma-high 10 1.05 0.20-5.45 1.10 0.29-4.20
Triple-negative
Stroma-low 36 0.010 0.231
Stroma-high 26 2.60 1.26-5.39 1.46 0.78-2.73




SUPPLEMENTARY TABLE 2. Prognostic value of the immune status stratified for 
breast cancer subtypes (n = 279).
Recurrence-free period Overall survival
n HR 95% CI p-value HR 95% CI p-value
Luminal A
High IS 33 <0.001 0.010
Intermediate IS 123 1.53 0.80-2.94 1.72 0.97-3.05
Low IS 36 3.53 1.75-7.14 2.65 1.40-5.02
Luminal B
High IS 3 0.651 0.979
Intermediate IS 7 1.69 0.17-16.40 0.98 0.18-5.44
Low IS 0
HER2-like
High IS 2 0.999 0.801
Intermediate IS 11 0.75 0.15-3.84
Low IS 2 1.27 0.17-9.33
Triple-negative
High IS 12 0.003 0.011
Intermediate IS 36 2.25 0.65-7.78 3.07 1.06-8.87
Low IS 14 6.39 1.79-22.84 5.54 1.79-17.18
Abbreviations: HER2 = human epidermal growth factor receptor 2, IS = immune status
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In the last decade, the tumor microenvironment has shown to play an important 
role in tumor progression. Still, no markers concerning the microenvironment 
have been implemented in clinical decision making. The research presented in this 
thesis emphasizes the prognostic value of the tumor-stroma ratio (TSR), a method 
focusing on the tumor microenvironment. The TSR assessment is performed by 
the scoring method developed by Mesker et al. on routine hematoxylin and eosin 
(H&E) stained tissue slides of the primary tumor (1). Various validation studies 
demonstrated that the TSR is a reliable, simple, quick and inexpensive parameter 
with a good to a very good inter-observer agreement, as described in the review 
in chapter 2. This review showed a significant association between a poor clinical 
outcome and tumors with a high amount of stroma in five out of seven studies. The 
two studies which were not in line with the previous results assessed the amount 
of stroma using semi-automated point counting. This method assessed the TSR 
in only two fields of 9 mm2 selected at the leading and non-leading edge of the 
tumor. This semi-automated scoring method is in contrast to the other studies 
which performed the TSR scoring on the most stroma-abundant area using a 10x 
objective as described by Mesker and colleagues.
Breast cancer is a heterogeneous disease. Subgroup analyses are essential to 
evaluate the clinical value of the TSR as a prognostic parameter. The clinical 
value of TSR might differ for the various subgroups, for example, receptor status 
or histological type. A challenge is the relatively large amount of patients required 
for adequate statistical power. Previously published research represented not all 
subgroups adequately, although most analyses showed a worse clinical outcome 
in patients with stroma-high tumors. Chapter 2 presented an overview of these 
results. To validate the prognostic value of the TSR in clinically important 
subgroups, a large UK cohort of 1794 primary breast cancer patients, primarily 
treated with surgery in the Nottingham City Hospital between 1993 and 2002, was 
analyzed. Chapter 3 described this retrospective study. The results showed that 
the prognostic value of the TSR was more pronounced in patients with grade III 
tumors compared to patients with grade I and II tumors. Moreover, observations 
showed a more pronounced prognostic effect of the TSR in patients with triple-
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negative tumors compared to nontriple-negative tumors. Comparable hazard ratios 
and confidence intervals for the TSR were observed in an independent Dutch cohort 
consisting of 737 early breast cancer patients diagnosed in the Netherlands Cancer 
Institute between 1990 and 1999. Age, tumor size, histology, estrogen receptor 
(ER) status, progesterone receptor (PR) status, human epidermal growth factor 
receptor 2 (HER2) status and lymph node status did not modify the prognostic 
value of the TSR.
The cohort from Nottingham City Hospital was scored using a digital version 
of the method developed by Mesker et al., showing the possibility of the TSR 
assessment on digital images. Digital pathology is becoming more important in 
current routine diagnostics. Advantages are, for example, availability of annotations 
and measurement tools, easier comparison between multiple slides, accessibility in 
sharing images for second opinions and/or extern research collaborations. A logical 
next step after the digitalization of images is the automation of the TSR, which 
is currently performed in collaboration with the University of Nijmegen. Visual 
TSR assessment is reliable, simple and quick, and accessible for all pathology 
laboratories. With the increased interest in automated pathology to handle the 
expanding numbers of analyses, automation of the TSR is desirable.
Chapter 4 illustrated the observation of a significant association between age and 
intra-tumoral stroma percentage assessed with the TSR. The results showed that the 
intra-tumoral amount of stroma increases with age. Different processes associated 
with the tumor and its microenvironment may play a role in the explanation of 
this observation, such as age-related alterations in the mamma, senescence of 
cells, changes in immune function and hormonal status. Additionally, chapter 4 
evaluated the prognostic value of the TSR in breast cancer patients of 70 years and 
older. Evaluation of prognostic markers in older patients is important because of 
a survival gap between younger and older patients with breast cancer, which may 
be caused partly by undertreatment. Currently, there are no specific guidelines 
concerning chemotherapy for older patients with breast cancer. Evidence-based 
treatment and accurate risk stratification are often not available since older patients 
are frequently excluded from studies. Comorbidities, which may strongly influence 




improve risk stratification in this specific group of patients are important for 
an accurate prognostic prediction regarding the additional benefit of adjuvant 
systemic therapy and can help patients and clinicians in shared-decision making. 
Unfortunately, so far, the TSR is likely to have no prognostic value in older patients 
with breast cancer.
Many efforts have been made to determine the best and the least invasive treatment 
of the axilla in breast cancer patients with positive axillary lymph nodes. There is 
a clinical need for an additional prognostic marker to improve risk stratification 
and personalized therapy.
In chapter 5 the prognostic value of the TSR in tumor-positive lymph nodes in 
addition to the prognostic value of the TSR in the primary tumor in 191 patients was 
evaluated. The results showed a statistically significant difference between primary 
tumor stroma-low/lymph node stroma-low and primary tumor stroma-high/lymph 
node stroma-high for the relapse-free period, with recurrence rates of 42% versus 
92%, respectively. The results in this study suggested that the assessment of 
the TSR in tumor-positive lymph nodes had additional value compared to the 
assessment of the primary tumor alone. Moreover, the strength of this study was the 
follow-up period of 15 years. The lymph nodes evaluated in this study were resected 
during axillary lymph node dissection, because the sentinel lymph node procedure 
was not part of standard clinical care. Compared to modern-day survival rates, 
the patients in this study had a relatively worse prognosis. Furthermore, a notable 
observation was the heterogeneity between the stroma category of the primary 
tumor and the lymph nodes in 52.9% of patients. A relatively high number of 
patients had stroma-high primary tumors and stroma-low lymph nodes. Literature 
shows that gene expression patterns differ between the primary tumor and the 
tumor disseminated to the lymph nodes. Downregulation of genes associated 
with cell-extracellular matrix (ECM) interaction, ECM remodeling, epithelial-
mesenchymal transition (EMT) and loss of basement membrane are observed in 
the invaded lymph nodes compared to the primary tumor, which could confirm 
our observation of heterogeneity.
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In chapter 6, the added value of immune markers to the TSR was evaluated in 
344 patients with breast cancer without distant metastasis. Six markers involved 
in the immune response were chosen based on their interactions in tumor control 
and escape; HLA-E, HLA-G, classical HLA class I, natural killer cells, cytotoxic 
T lymphocytes (CTLs) and regulatory T cells (Tregs). Based on the interaction 
of these cells, the immune status of the tumors was divided into three categories: 
high, intermediate and low. For example, tumors with a high immune status showed 
expression of classical HLA class I, high infiltration of cytotoxic T cells and no 
infiltration of regulatory T cells. On the other hand, tumors with a low immune 
status showed no expression of classical HLA class I and no natural killer cell and 
regulatory T cell infiltration. As hypothesized at the start of this study, the results 
confirmed that breast cancer patients with a stroma-low tumor combined with a 
high immune status had a far more favorable prognosis compared to patients with 
a stroma-high tumor and a low immune status. The classical HLA class I was the 
most important prognostic determinant of the analyzed set of immune markers.
FUTURE PERSPECTIVES
Based on the published literature and the research presented in this thesis, the 
TSR is likely to be an independent prognostic parameter. The future perspectives 
of the TSR are two-sided, namely (1) clinical implementation of the TSR as a 
prognostic parameter and (2) research into the biological mechanism of stroma-
low and stroma-high tumors in the search for new stroma derived markers for 
diagnostics, prognosis, disease monitoring and targeted therapy.
A next step toward clinical implementation is adding the TSR to the frequently 
used online prediction tool PREDICT. There is a clinical need to improve risk 
stratification to help clinicians and patients in shared decision-making toward 
personalized therapy. Implementation of the TSR in daily clinical practice needs 
further international validation in a very large retrospective assembled cohort 
consisting of patients with 10 years of follow-up or in a large prospective study. 
For clinical implementation of the TSR in colon cancer patients, the UNITED 




study to validate the TSR in colon cancer patients. This study also includes training 
of pathologists for the assessment of the TSR to evaluate the inter-observer and 
intra-observer variation. Advantages of a prospective study for breast cancer are 
data collection and more up-to-date treatment regimes, but disadvantages are the 
long follow-up time of 10 years and the logistic challenge of including patients in 
many hospitals across the globe.
The PREDICT tool is used in patients primarily treated with surgery. The group 
of breast cancer patients treated with neoadjuvant chemotherapy is increasing. 
Therefore, it is of interest to evaluate the prognostic and predictive value of the TSR 
on core-needle biopsies of primary breast tumors instead of H&E slides originating 
from the primary tumor. Dekker et al. observed no association between the TSR 
assessed on H&E stained slides from tumor biopsies and complete pathological 
response to chemotherapy in 175 tumors of patients included in the NEOZOTAC 
trial (2). Besides, the authors evaluated the predictive value of stromal organization 
on tumor biopsies for the response to neoadjuvant chemotherapy and concluded that 
stromal organization was related to pathological response to chemotherapy (2). This 
study is the only publication on the TSR evaluation performed on core biopsies of 
breast tumors so far. For a more decisive conclusion, evaluation of a larger cohort 
is desirable. It would be of additional value if the assessment of the TSR on tumor 
biopsies could help to discriminate which patients are likely to respond to pre-
operative chemotherapy in addition to standard pathological parameters and the 
relation to clinical outcome. This might result in an improved selection of patients 
for preoperative chemotherapy.
In this thesis, the additional prognostic value of the TSR in tumor positive lymph 
nodes resected during axillary lymph node dissection (ALND) to the TSR in the 
primary tumor was evaluated. In the last years, the intention of axillary management 
is the de-escalation of treatment and the reduction of morbidity associated with 
ALND. The omission of ALND is widely discussed in patients with 1 or 2 tumor-
positive sentinel nodes in clinically node-negative disease (3-6). Evaluation of 
the TSR in tumor-positive sentinel nodes may add to better stratification of low 
or high-risk patients and finally to improve treatment decision making. In case a 
patient receives pre-operative chemotherapy, a core needle biopsy, instead of fine 
needle aspiration for cytology, of the lymph node suspicious for tumor involvement 
157
SUMMARY, GENERAL DISCUSSION AND FUTURE PERSPECTIVES
might be performed to define the TSR. However, this may not be possible if the 
sentinel node is small.
Further research on the influence of the tumor stroma and the immune response 
regarding prognostication and interaction would be beneficial. Immune cells 
are an important component of the tumor microenvironment. Much research is 
performed on the prognostic role of tumor-infiltrating lymphocytes (TILs). The 
main components of TILs in breast cancer are CD4+ and CD8+ cells. Scoring of 
TILs are, like the TSR, assessed on standard H&E slides. High infiltration of TILs 
is associated with a better outcome (7-11). Especially stromal TILs have shown 
prognostic and predictive value (for example pathological complete response to 
neoadjuvant chemotherapy) in breast cancer patients, in particular in patients with 
triple-negative breast cancer and human epidermal receptor 2 (HER2) positive 
cancer (11). In this thesis, the TSR was combined with the immune status of tumors 
whereby the immunohistochemical evaluation of cytotoxic T lymphocytes (CTLs) 
and regulatory T cells (Tregs) was included as part of six immune markers (12, 
13). As CD8+ T cells are generally CTLs and CD4+ T cells are helper T cells and 
Tregs, there is overlap with the immune status presented in this thesis. On the other 
hand, the inflammatory cells in the stroma are part of the stroma percentage score. 
Therefore, combining the TSR and TILs might strengthen each other.
The programmed death-ligand 1/programmed death-1 (PD-L1/PD-1) signaling 
pathway has become an important research topic in recent years. Inhibition and 
activation of T cells as a result of targeting this signaling pathway can influence 
the tumor microenvironment by preventing tumor immune evasion. Jiang et al. 
suggests in a review that inflammatory factors in the tumor microenvironment may 
induce PD-L1 and thereby influence the therapeutic efficiency of blocking PD-L1/
PD-1 (14). It would be valuable to evaluate if the TSR could help in predicting 
therapeutic efficiency.
Research into the biological mechanism of stroma-low and stroma-high tumors in 
the search for new stroma derived markers may lead to new diagnostic, prognostic, 
monitoring and therapeutic opportunities. Stroma-high tumors likely reflect an 
activated stroma, supporting tumor aggressiveness. However, the underlying 




unknown. In-depth research is required to understand the biological differences in 
the tumor stroma of patients with stroma-low and stroma-high tumors, for example 
by evaluating gene expression profiles. Cancer-associated fibroblasts (CAFs), 
vascular endothelial growth factor, stromal cell-derived factor 1, platelet-derived 
growth factor, and transforming growth factor-β are thought to be strongly involved 
in cancer progression. CAFs are one of the most important components of the tumor 
microenvironment and play a role in remodeling the tumor microenvironment. 
Through the secretion of growth factors, cytokines and chemokines, CAFs enable 
tumor cells to invade the tumor microenvironment.
Regarding the improvement of therapeutic agents based on the stromal 
compartment, CAFs are promising. However, specific markers on CAFs are still 
lacking and therefore restrain direct depletion. Another way of influencing CAFs 
is via indirect routes, such as targeting processes influencing CAF activation or 
effectors. In a preclinical trial based on a triple-negative breast cancer model, 
doxorubicin combined with an antifibrotic agent pirfenidone inhibited tumor 
growth and metastasis. This agent has an anti-TGF-beta activity and may reduce 
collagen and hyaluronan levels (15). More knowledge about the role of the tumor 
microenvironment in chemo-resistance is also crucial to improve the success of 
chemotherapy.
Stromal markers can also be used for optical imaging techniques in oncological 
breast surgery, which could help to optimize the surgical procedure. Current 
preoperative imaging techniques do not provide enough information about the 
tumor borders resulting in surgical reintervention in approximately 25% of patients 
undergoing breast-conserving surgery. Intra-operative visualization techniques are 
therefore desirable, and tumor stroma might be a valuable source.
Furthermore, specific reliable markers originated from the stromal compartment 
can be used as tumor tracers, for example in positron emission tomography scan 
(PET-scan). These markers can be useful in monitoring disease progression, 
detecting cancer, determining disease aggressiveness and/or drug effectiveness 
before histology is available. For example, diagnostic dosages of drugs can be 
applied to patients to evaluate if the drug reaches the tumor and could, later on, 
be used in developing new therapeutics. Additionally, recently, the TSR was 
correlated with the images of a breast MRI. The authors concluded that short-tau 
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inversion-recovery (STIR) T2 weighted imaging and dynamic sequence of breast 
MRI reflected the stromal compartment of invasive breast tumors (16). Finally, 
molecules in the blood released by the stromal compartment also have potential in 
the early detection of breast cancer. Tumor stroma specific molecules in the ‘liquid 
biopsy’ could be identified by, for example, a proteomic approach.
CONCLUSIONS
The new insights presented in this thesis contribute to a better understanding of 
the role of the TSR on predicting clinical outcome in subgroups of breast cancer 
patients and in combination with other prognostic parameters. Furthermore, the 
described research is important for further research toward clinical implementation 
of the TSR and might finally be useful for decision-making regarding therapy. 
Moreover, molecular research of the stromal compartment in the near future is 
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Borstkanker is de meest voorkomende oorzaak van kanker gerelateerde sterfte 
bij vrouwen. De overleving van vrouwen met borstkanker is de laatste jaren 
toegenomen door enerzijds het bevolkingsonderzoek en anderzijds verbeterde 
behandelingen. Om de overleving verder te verbeteren is het nodig dat het risico 
op terugkeer of overlijden ten gevolge van borstkanker beter wordt ingeschat. Door 
een betere risicoschatting kunnen vrouwen op maat worden behandeld, waardoor 
onder- en overbehandeling zoveel mogelijk kan worden voorkomen. Dit houdt in 
dat er een betere afweging gemaakt kan worden tussen het risico op terugkeer van 
ziekte en bijwerkingen van chemotherapie, zoals hartfalen en cognitieve disfunctie. 
De voorspelling over het verloop van een ziekte wordt ook wel prognose genoemd.
Het inschatten van de agressiviteit van de ziekte gebeurt in de klinische praktijk op 
basis van kenmerken van de tumorcellen, zoals hormoongevoeligheid, gradering 
en de grootte van de tumor. In de afgelopen jaren is het duidelijk geworden dat de 
omgeving waarin de tumorcellen zich bevinden, ook wel het tumorstroma genoemd, 
van belangrijke invloed is op de ontwikkeling van kanker. Het tumorstroma 
bestaat uit verschillende componenten, zoals bindweefsel, met daarin fibroblasten, 
cellen van de bloedvaten en cellen van het afweersysteem. De interactie tussen 
kankercellen en stromacellen is complex en verandert bij het voortschrijden van 
de ziekte. Tot op heden zijn er echter nog geen specifieke tumorstroma markers 
beschikbaar die klinisch toepasbaar zijn.
In dit proefschrift wordt de tumor-stroma ratio bestudeerd als marker om de mate 
van agressiviteit van borstkanker beter in te schatten. Het grote voordeel van de 
tumor-stroma ratio is dat de beoordeling van deze parameter simpel, snel en relatief 
goedkoop is. Het scoren vindt namelijk plaats door middel van het beoordelen van 
het tumorweefsel met een conventionele lichtmicroscoop. Tumorweefsel wordt 
in de huidige routine diagnostiek al uitvoerig door de patholoog beoordeeld om 
bijvoorbeeld het soort kanker en de uitgebreidheid van het proces te bepalen. 
De tumor-stroma ratio is een maat om de proportie van tumorcellen versus 
stromacellen uit te drukken in het meest stroma bevattende deel van een tumor. 
Deze scoringsmethode is als eerste beschreven door Mesker en collega’s in 
darmkankerweefsel en daarna verder onderzocht in andere kankersoorten. De 
meeste studies laten zien dat patiënten met veel stroma in de tumor (stroma-hoog) 
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eerder kans hebben op terugkeer van ziekte en overlijden ten gevolge van kanker 
ten opzichte van patiënten met een tumor die weinig stroma (stroma-laag) bevat.
Het onderzoek beschreven in dit proefschrift levert een bijdrage aan het beter 
begrijpen van (1) de rol van de tumor-stroma ratio als prognostische factor in 
verschillende subgroepen borstkankerpatiënten en (2) de voorspellende waarde van 
de tumor-stroma ratio in combinatie met andere tumor gerelateerde parameters.
Hoofdstuk 2 begint met een overzicht van artikelen die gepubliceerd zijn waarin 
de prognostische waarde van de tumor-stroma ratio in vrouwen met borstkanker 
wordt onderzocht. Dit review laat zien dat in vijf van de zeven studies patiënten 
met een stroma-hoog tumor een slechtere klinische uitkomst hebben ten opzichte 
van patiënten met een stroma-laag tumor. In de twee studies waarin dit effect niet 
wordt gezien, is een andere methode gebruikt om de tumor-stroma ratio te bepalen, 
namelijk een semi-automatische punttelling. Een belangrijk verschil is dat bij deze 
methode niet het meest stromarijke deel wordt geselecteerd, zoals bij de methode 
van Mesker en collega’s. Het review in hoofdstuk 2 laat tevens zien dat de tumor-
stroma ratio niet alleen in de algemene borstkanker populatie een prognostische 
waarde heeft, maar ook in een aantal klinisch relevante subgroepen.
Hoofdstuk 3 onderzoekt de waarde van de tumor-stroma ratio in een grote groep 
vrouwen met borstkanker en kijkt tevens naar de prognostische waarde van de 
tumor-stroma ratio in de meest klinisch relevante subgroepen. Hiervoor worden 
de studiegegevens van 1794 patiënten afkomstig van de University of Nottingham 
(Engeland) gebruikt, alsmede de gegevens van 737 patiënten afkomstig van het 
Nederlandse Kanker Instituut-Antoni van Leeuwenhoek (Nederland). De studie 
illustreert dat in de totale patiëntengroep, een stroma-hoog tumor geassocieerd 
is met een klinisch slechtere uitkomst. Deze studie laat tevens zien dat de 
voorspellende waarde van de tumor-stroma ratio in de meeste klinisch relevante 
subgroepen niet verschilt ten opzichte van het effect in de totale patiëntengroep. 
Een opvallende bevinding is dat in patiënten met een graad III tumor een beter 
onderscheidend vermogen van de tumor-stroma ratio wordt gezien, alsmede in 
patiënten met triple-negatieve borstkanker. De mate van gradering geeft aan in 
hoeverre de kankercellen lijken op gezond weefsel, onderverdeeld in graad I tot 




gezonde cellen van het borstweefsel. Triple-negatieve borstkanker is niet gevoelig 
voor de hormonen progesteron en oestrogeen en daarnaast ontbreekt het eiwit 
humane epidermale groeifactor receptor 2. Deze vorm van borstkanker is vaak 
agressiever, waarbij de ziekte vaker terugkomt in vergelijking met hormoon-
gevoelige borstkanker.
In hoofdstuk 4 is onderzocht hoe de hoeveelheid stroma, bepaald met de tumor-
stroma ratio, verandert met de leeftijd. De resultaten van dit onderzoek laten zien 
dat het stroma toeneemt met de leeftijd van de patiënt. Dit is een nieuwe bevinding 
die nog niet eerder is gepubliceerd en draagt bij aan de opvatting dat tumoren bij 
oudere vrouwen verschillen van tumoren bij jongere vrouwen. Het immuunsysteem 
functioneert namelijk anders naarmate men verouderd, maar ook de hormonale 
status verandert door de jaren heen. De resultaten in dit hoofdstuk tonen aan dat 
er geen voorspellende waarde is van de tumor-stroma ratio voor het voorspellen 
van de overleving bij vrouwen van 70 jaar en ouder.
In het volgende hoofdstuk, hoofdstuk 5, wordt de toegevoegde waarde van de 
tumor-stroma ratio in tumor-positieve lymfeklieren in de oksel onderzocht. 
De resultaten laten zien dat het bepalen van de tumor-stroma ratio in positieve 
lymfeklieren toegevoegde waarde heeft ten opzichte van de bepaling van de tumor-
stroma ratio in de primaire tumor alleen. Een andere belangrijke bevinding is het 
verschil ten aanzien van de hoeveelheid stroma in de primaire tumoren en de tumor 
bevattende oksellymfeklieren.
Het laatste onderzoek dat gepresenteerd wordt in hoofdstuk 6 gaat over de 
toegevoegde waarde van immuunmarkers op de prognostische waarde van de 
tumor-stroma ratio. Er zijn zes verschillende immuunmarkers onderzocht die 
gekozen zijn op basis van hun interactie en rol in tumorontwikkeling: humaan 
leukocytenantigenen (HLA)-E, HLA-G, klassieke HLA klasse I, cytotoxische 
T-cellen en regulatoire T-cellen. De resultaten laten zien dat patiënten met een 
stroma-hoog tumor met een lage immuunstatus de slechtste overleving hebben 
en patiënten met een stroma-laag tumor en een hoge immuunstatus de beste 
overleving. Daarnaast is aangetoond dat klassieke HLA klasse I de meest bepalende 
factor van de zes immuunmarkers is.
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Vervolgonderzoek naar de prognostische waarde van de tumor-stroma ratio zal 
zich richten op de klinische implementatie van deze parameter, bijvoorbeeld door 
toevoeging van de tumor-stroma ratio aan het online predictiemodel PREDICT. 
Dit model wordt in Nederland door oncologen gebruikt om de overlevingskansen 
en de toegevoegde waarde van aanvullende chemotherapie, hormonale therapie 
en immunotherapie te voorspellen. Indien door middel van de toevoeging van 
de tumor-stroma ratio aan de PREDICT een nauwkeurigere inschatting kan 
worden gemaakt over de agressiviteit van de tumor, kan dit mogelijk leiden tot 
nog gerichtere therapie. Verder is het zeer interessant om meer inzicht te krijgen 
in biologische processen in het tumorstroma, met name in het biologische verschil 
tussen stroma-laag en stroma-hoog tumoren. Dergelijk onderzoek zou potentieel 
nieuwe stromale markers kunnen opleveren, welke van invloed kunnen zijn op 
het nauwkeuriger bepalen van de prognose van een patiënt met borstkanker. 
Tevens kunnen nieuwe stromale markers bijdragen aan het optimaliseren van de 
diagnostiek, monitoring en ontwikkeling van gerichte therapeutische strategieën. 
Hierbij kan worden gedacht aan image guided surgery, betere visualisatie van de 
tumor op scans en specifieke therapie die aangrijpt op stromacellen die van belang 
zijn voor tumorontwikkeling.
Samengevat laat het onderzoek gepresenteerd in dit proefschrift zien dat de tumor-
stroma ratio een mogelijk veelbelovende prognostische marker is. De nieuwe 
inzichten beschreven in dit proefschrift dragen bij aan de kennis voor verder 
onderzoek richting de klinische implementatie van de tumor-stroma ratio.
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